

BCG vaccine

Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against tuberculosis

Ebola vaccine

Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Japanese encephalitis vaccine

Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Medicines for COVID-19

Section

Medicines for COVID-19

Refer to WHO living guidelines

Indications

COVID-19

Abacavir

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Solid: 300 mg tablet (as sulfate)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Abacavir + dolutegravir + lamivudine

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid > tablet: 60 mg (as sulfate) + 5 mg + 30 mg (dispersible, scored)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Abacavir + lamivudine

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Abacavir + lamivudine + lopinavir + ritonavir

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Abemaciclib

Section

Targeted therapies

Indications

Therapeutic equivalent to [palbociclib](#) for

Other specified malignant neoplasms of breast

Abiraterone

Section

Hormones and antihormones

Oral > Solid: 250 mg; 500 mg

Indications

Malignant neoplasms of prostate

Acamprosate calcium

Section

Medicines for alcohol use disorders

Oral > Solid > tablet: 333 mg

Indications

Disorders due to use of alcohol

Acenocoumarol

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to warfarin for Other specified diseases of arteries or arterioles Therapeutic equivalent to warfarin for Venous thromboembolism Therapeutic equivalent to warfarin for Cerebral ischaemic stroke due to embolic occlusion Therapeutic equivalent to warfarin for Atrial fibrillation

Acetazolamide

Section	Indications
Ophthalmological preparations > Miotics and antiglaucoma medicines Oral > Solid: 250 mg	Primary open-angle glaucoma

Acetic acid

Section	Indications
Ear, nose and throat medicines [c] Local > Otological > drops: 2% solution	Infectious diseases of external ear

Acetylcysteine

Section	Indications
Antidotes and other substances used in poisonings > Specific Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule Oral > Liquid: 10%; 20%	Acute or subacute hepatic failure Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs

Acetylsalicylic acid

Section	Indications
Anti-platelet medicines Oral > Solid: 100 mg	Acute myocardial infarction Cerebral ischaemic stroke
Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs) Oral > Solid: 100 to 500 mg Local > Rectal > Suppository: 50 to 150 mg	Pain
Medicines for acute migraine attacks Oral > Solid: 300 to 500 mg	Migraine
Medicines for juvenile joint diseases Local > Rectal > Suppository: 150 mg; 300 mg Oral > Solid > dispersible tablet: 75 mg; 300 mg; 500 mg Oral > Solid > tablet: 75 to 500 mg	Acute rheumatic fever without mention of heart involvement Mucocutaneous lymph node syndrome Juvenile idiopathic arthritis

Acetylsalicylic acid + atorvastatin + ramipril

Section	Indications
Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease Oral > Solid > tablet: 100 mg + 20 mg + 2.5 mg; 100 mg + 20 mg + 5 mg; 100 mg + 20 mg + 10 mg; 100 mg + 40 mg + 2.5 mg; 100 mg + 40 mg + 5 mg; 100 mg + 40 mg + 10 mg	Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke

Acetylsalicylic acid + simvastatin + ramipril + atenolol + hydrochlorothiazide

Section	Indications
Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease Oral > Solid > tablet: 100 mg + 20 mg + 5 mg + 50 mg + 12.5 mg	Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke

Aciclovir

Section

[Ophthalmological preparations > Anti-infective agents](#)

Local > Ophthalmological > Ointment: 3% w/w

[Antiherpes medicines](#)

Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)

Oral > Liquid: 200 mg per 5 mL

Oral > Solid: 200 mg tablet

Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)

[Medicines for viral central nervous system infections](#)

Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)

Oral > Liquid: 200 mg per 5 mL

Oral > Solid: 200 mg tablet

Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)

Indications

Herpes simplex keratitis

Herpes simplex infections

Zoster

Varicella

Herpes simplex infections

Zoster

Varicella

Acclidinium

Section

[Antiasthmatic and medicines for chronic obstructive pulmonary disease](#)

Indications

Therapeutic equivalent to [tiotropium bromide](#) for

Chronic obstructive pulmonary disease

Activated charcoal

Section

[Antidotes and other substances used in poisonings > Non-specific](#)

Oral > Liquid: 50 mg granules for oral suspension

Indications

Unspecified injury, poisoning or certain other consequences of external causes

Adalimumab

Section	Indications
Immunomodulators for non-malignant disease Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL	Axial spondyloarthritis Crohn disease site Rheumatoid arthritis
Medicines for juvenile joint diseases Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL	Juvenile idiopathic arthritis
Dermatological medicines > Medicines affecting skin differentiation and proliferation Parenteral > General injections > SC: 10 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.; 80 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.	Psoriasis of unspecified type

Afatinib

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung

Albendazole

Section	Indications
Intestinal anthelmintics Oral > Solid > tablet: 400 mg (chewable, scored)	Echinococcosis Enterobiasis Trichuriasis Hookworm diseases Cysticercosis Ascariasis
Cysticidal medicines Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)	Other specified echinococcosis Cysticercosis of central nervous system
Antifilarials Oral > Solid > tablet: 400 mg (chewable, scored)	Lymphatic filariasis

Alcohol based hand rub

Section	Indications
Disinfectants Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol	Denatured alcohol

Alcuronium

Section	Indications
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors Parenteral > General injections > IV: 5 mg per mL in 2 mL ampoule (alcuronium chloride)	Muscle relaxants

Alfacalcidol

Section	Indications
Medicines for endocrine disorders Oral > Liquid: 2 µg per mL Oral > Solid > capsule: 0.25 µg; 1 µg	Chronic kidney disease, stage unspecified Disorders of vitamin D metabolism or transport

All-trans retinoic acid

Section	Indications
Targeted therapies Oral > Solid: 10 mg capsule	Acute myeloid leukaemia with recurrent genetic abnormalities

Allopurinol

Section	Indications
Medicines used to treat gout Oral > Solid: 100 mg	Gout
Supportive medicines Parenteral > General injections > IV: 500 mg (as sodium) powder for injection Oral > Solid: 100 mg; 300 mg	Tumour lysis syndrome

Alprostadil (prostaglandin E1)

Section	Indications
Medicines administered to the neonate [c] Parenteral > General injections > IV: 0.5 mg per mL in alcohol	Other specified congenital anomaly of great arteries including arterial duct

Alteplase

Section

Thrombolytic medicines

Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection

Indications

Cerebral ischaemic stroke

Amidotrizoate

Section

Diagnostic agents > Radiocontrast media

Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)

Indications

Amidotrizoate

Amikacin

Section

Ophthalmological preparations > Anti-infective agents

Access group antibiotics

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Indications

Therapeutic equivalent to [gentamicin](#) for

Other specified conjunctivitis

Therapeutic equivalent to [gentamicin](#) for

Infectious blepharitis

First choice

Neutropenia (high-risk)

co-prescribed with [cefotaxime](#)

Inflammatory and other diseases of prostate (severe)

co-prescribed with [cefotaxime](#)

Acute pyelonephritis (severe)

co-prescribed with [ceftriaxone](#)

Inflammatory and other diseases of prostate (severe)

co-prescribed with [ceftriaxone](#)

Acute pyelonephritis (severe)

Second choice

co-prescribed with [cloxacillin](#)

Sepsis without septic shock

Antituberculosis medicines

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Multi-drug resistant *Mycobacterium tuberculosis*

Amiloride

Section

Diuretics

Oral > Solid: 5 mg (hydrochloride)

Indications

Oedema

Ascites

Amiodarone

Section

Antiarrhythmic medicines

Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride)

Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)

Indications

Cardiac arrhythmia

Amitriptyline

Section

Medicines for depressive disorders

Oral > Solid: 25 mg; 75 mg

Medicines for migraine prophylaxis

Oral > Solid > tablet: 25 mg

Medicines for other common symptoms in palliative care

Oral > Liquid: 25 mg per 5 mL

Oral > Solid > tablet: 25 mg; 10 mg; 75 mg

Indications

Depressive disorders

Migraine

Palliative care

Amlodipine

Section

Antihypertensive medicines

Oral > Solid: 5 mg (as maleate, mesylate or besylate)

Indications

Essential hypertension

Amodiaquine

Section

Antimalarial medicines > Medicines for curative treatment

Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)

Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Amodiaquine - sulfadoxine + pyrimethamine

Section

[Antimalarial medicines](#) > [Medicines for chemoprevention](#)

Oral > Solid > dispersible tablet: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package; 75 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 150 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package

Indications

Malaria

Amoxicillin

Section

Access group antibiotics

Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid

Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection

Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)

Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)

Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid

Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)

Medicines for bacterial central nervous system infections

Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid

Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection

Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)

Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)

Indications

First choice

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Acute malnutrition in infants, children or adolescents (uncomplicated) [children]

Acute malnutrition in infants, children or adolescents (complicated) [children]

Acute pharyngitis

Chronic obstructive pulmonary disease with acute exacerbation

Periapical abscess without sinus

Acute otitis media

Acute sinusitis

co-prescribed with gentamicin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with gentamicin

Sepsis without septic shock

Second choice

Bacterial meningitis

Other indications

Infectious cystitis

Bacterial infection of unspecified site

Second choice

Bacterial meningitis

Amoxicillin + clavulanic acid

Section

Access group antibiotics

Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection

Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid

Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)

Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)

Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Antituberculosis medicines

Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid

Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt)

Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

First choice

Peritoneal abscess (mild-moderate)

Neutropenia (low-risk)

Other specified pneumonia (Hospital-acquired pneumonia)

Infectious cystitis

Chronic obstructive pulmonary disease with acute exacerbation

Peritonitis (mild-moderate)

Acute sinusitis

Bacterial cellulitis, erysipelas or lymphangitis

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Second choice

Osteomyelitis or osteitis

Acute otitis media

Other specified prophylactic measures

Bacterial infection of joint

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

co-prescribed with clarithromycin

Bacterial pneumonia (Community-acquired pneumonia - severe)

Other indications

Bacterial infection of unspecified site

Multi-drug resistant Mycobacterium tuberculosis

Amphotericin B

Section

Antifungal medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)

Antileishmaniasis medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)

Indications

Blastomycosis

Cryptococcosis

Candidosis

Coccidioidomycosis

Histoplasmosis

Sporotrichosis

Aspergillosis

Visceral leishmaniasis

Ampicillin

Section

Access group antibiotics

Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection

Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension

Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

First choice

co-prescribed with [gentamicin](#)

[Peritoneal abscess \(severe\)](#)

co-prescribed with [gentamicin](#)

[Sepsis without septic shock](#)

co-prescribed with [gentamicin](#)

[Peritoneal abscess \(mild-moderate\)](#)

co-prescribed with [gentamicin](#)

[Peritonitis \(severe\)](#)

co-prescribed with [gentamicin](#)

[Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#)

co-prescribed with [gentamicin](#)

[Peritonitis \(mild-moderate\)](#)

co-prescribed with [gentamicin](#)

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#)

Second choice

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Second choice

[Bacterial meningitis](#)

Medicines for bacterial central nervous system infections

Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection

Anakinra

Section

Medicines for juvenile joint diseases

Parenteral > General injections > SC: 100 mg per 0.67 mL in pre-filled syringe

Indications

[Juvenile systemic arthritis](#)

Anastrozole

Section

Hormones and antihormones

Oral > Solid: 1 mg tablet

Indications

[Other specified malignant neoplasms of breast](#)

[Malignant neoplasms of breast](#)

Anidulafungin

Section

Antifungal medicines

Indications

Therapeutic equivalent to [micafungin](#) for

Systemic or invasive candidosis

Ansuvimab

Section

Medicines for Ebola virus disease

Parenteral > General injections > IV: 400 mg powder for injection

Indications

Ebola virus disease

Anti-D immunoglobulin

Section

Human immunoglobulins

Parenteral > General injections > IV: 250 µg in single-dose vial

Parenteral > General injections > IM: 250 µg in single-dose vial

Indications

Rh incompatibility reaction

Maternal care for red cell antibodies

Anti-rabies immunoglobulin

Section

Human immunoglobulins

Parenteral > General injections > IM: 150 IU per mL in vial

Parenteral > Locoregional injections > Other: 150 IU per mL in vial

Indications

Rabies

Anti-rabies virus monoclonal antibodies

Section

[Immunologicals](#) > [Sera, immunoglobulins and monoclonal antibodies](#)

Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)

Indications

Rabies

Anti-tetanus immunoglobulin

Section

Human immunoglobulins

Parenteral > General injections > IM: 500 IU in vial

Indications

Tetanus

Antirabies hyperimmune serum

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies
Parenteral > General injections > unspecified: 1000 IU in 5 mL ampoule

Indications

Rabies

Antivenom immunoglobulin

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies
Parenteral > General injections > IV:

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Antivenom sera

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies
Parenteral > General injections > IV:

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Apixaban

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [dabigatran](#) for

Venous thromboembolism

Therapeutic equivalent to [dabigatran](#) for

Other specified atrial fibrillation

Aprepitant

Section

Antiemetic medicines
Oral > Liquid: 125 mg powder for oral suspension (in sachet)
Oral > Solid > capsule: 80 mg; 125 mg; 165 mg

Indications

Nausea or vomiting

Aripiprazole

Section

Medicines for psychotic disorders
Parenteral > General injections > IM: 300 mg powder and solvent for suspension; 400 mg powder and solvent for suspension

Indications

Therapeutic equivalent to [risperidone](#) for

Schizophrenia or other primary psychotic disorders

Therapeutic equivalent to [paliperidone](#) for

Schizophrenia or other primary psychotic disorders

Arpraziquantel

Section

Antischistosomes and other antitrepatode medicines

Oral > Solid > dispersible tablet: 150 mg

Indications

Therapeutic equivalent to praziquantel for

Schistosomiasis

Arsenic trioxide

Section

Cytotoxic medicines

Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Artemether

Section

Antimalarial medicines > Medicines for curative treatment

Parenteral > General injections > IM: 20 mg per mL in 1 mL ampoule (oily injection); 40 mg per mL in 1 mL ampoule (oily injection)

Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Artemether + lumefantrine

Section

Antimalarial medicines > Medicines for curative treatment

Oral > Solid > dispersible tablet: 20 mg + 120 mg

Oral > Solid > tablet: 20 mg + 120 mg

Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Artesunate

Section

Antimalarial medicines > Medicines for curative treatment

Parenteral > General injections > IV: 60 mg in vial powder for injection; 30 mg in vial powder for injection; 120 mg in vial powder for injection

Local > Rectal > Other: 100 mg capsules

Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Artesunate + amodiaquine

Section

Antimalarial medicines > Medicines for curative treatment

Oral > Solid > tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg

Oral > Solid > tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg tablet

Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Artesunate + mefloquine

Section

[Antimalarial medicines](#) > [Medicines for curative treatment](#)

Oral > Solid > tablet: 25 mg + 50 mg (as hydrochloride); 100 mg + 200 mg (as hydrochloride)

Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Artesunate + pyronaridine

Section

[Antimalarial medicines](#) > [Medicines for curative treatment](#)

Oral > Solid > tablet: 60 mg + 180 mg (tetraphosphate)

Oral > Solid > granules: 20 mg + 60 mg (tetraphosphate)

Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Artesunate - sulfadoxine + pyrimethamine

Section

[Antimalarial medicines](#) > [Medicines for curative treatment](#)

Oral > Solid > tablet: 50 mg [3] + 500 mg + 25 mg [1] in copackage (scored)

Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Ascorbic acid

Section

[Vitamins and minerals](#)

Oral > Solid: 50 mg

Indications

Scurvy

Asparaginase

Section

[Cytotoxic medicines](#)

Powder for injection: 10 000 IU in vial.

Parenteral > General injections > unspecified: 10000 IU in vial powder for injection

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, not elsewhere classified

Atazanavir

Section

[Antiretrovirals](#) > [Protease inhibitors](#)

Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Atazanavir + ritonavir

Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Atenolol

Section

Antianginal medicines

Oral > Solid: 50 mg; 100 mg

Antihypertensive medicines

Oral > Solid: 50 mg; 100 mg

Indications

Angina pectoris

Essential hypertension

Therapeutic equivalent to [bisoprolol](#) for

Essential hypertension

Atezolizumab

Section

Immunomodulators

Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion

Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion

Indications

Other specified malignant neoplasms of bronchus or lung

Therapeutic equivalent to [pembrolizumab](#) for

Other specified malignant neoplasms of bronchus or lung

Therapeutic equivalent to [pembrolizumab](#) for

Adenocarcinoma of stomach

Hepatocellular carcinoma of liver

Atoltivimab + maftivimab + odesivimab

Section

Medicines for Ebola virus disease

Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial

Indications

Ebola virus disease

Atorvastatin

Section

Lipid-lowering agents

Indications

Therapeutic equivalent to [simvastatin](#) for

Mixed hyperlipidaemia

Therapeutic equivalent to [simvastatin](#) for

Coronary atherosclerosis

Atorvastatin + perindopril + amlodipine

Section

Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease

Oral > Solid > tablet: 20 mg + 5 mg + 5 mg; 20 mg + 10 mg + 10 mg; 40 mg + 5 mg + 5 mg; 40 mg + 10 mg + 10 mg

Indications

Chronic ischaemic heart disease

Atherosclerotic chronic arterial occlusive disease

Cerebral ischaemic stroke

Atracurium

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

Parenteral > General injections > IV: 10 mg per mL (besylate)

Indications

Muscle relaxants

Therapeutic equivalent to [vecuronium](#) for

Muscle relaxants

Atropine

Section

Diagnostic agents > Ophthalmic medicines

Ophthalmological preparations > Mydriatics

Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)

Preoperative medication and sedation for short-term procedures

Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule or vial (sulfate); 400 µg per mL in 1 mL ampoule or vial (sulfate)

Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule or vial (sulfate)

Indications

Therapeutic equivalent to [tropicamide](#) for

Cycloplegic drug

Anterior uveitis

Parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics

Exposure to or harmful effects of undetermined intent of pesticides

Axicabtagene ciloleucel

Section

Antineoplastics and supportive medicines

Cell suspension for infusion: 2×10^6 anti-CD19 CAR-positive viable T-cells per kg of body weight.

Indications

Diffuse large B-cell lymphomas

Axitinib

Section

Targeted therapies

Oral > Solid > tablet: 1 mg; 3 mg; 5 mg

Indications

Renal cell carcinoma of kidney, except renal pelvis

Azacitidine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 100 mg in vial powder for injection

Indications

Myeloid leukaemia

Azathioprine

Section

Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 50 mg in vial powder for injection (as sodium salt); 100 mg in vial powder for injection (as sodium salt)

Oral > Liquid: 10 mg per mL

Oral > Solid > tablet: 25 mg; 50 mg (scored)

Oral > Solid > tablet: 50 mg (scored)

Disease-modifying anti-rheumatic drugs (DMARDs)

Oral > Solid > tablet: 50 mg (scored)

Indications

Failure or rejection of transplanted organs or tissues

Relapsing-remitting multiple sclerosis

Rheumatoid arthritis, serology unspecified

Psoriatic arthritis

Azithromycin

Section

Ophthalmological preparations > Anti-infective agents

Local > Ophthalmological > Solution (eye drops): 1.5% eye drops

Watch group antibiotics

Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid

Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

Trachoma

First choice

Chlamydia trachomatis

Typhoid fever

Yaws

Paratyphoid fever

Cholera

Cholera [children]

Trachoma

co-prescribed with ceftriaxone

Gonococcal infection

Second choice

Infectious gastroenteritis or colitis without specification of infectious agent

co-prescribed with cefixime

Gonococcal infection

Aztreonam

Section

Reserve group antibiotics

Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

Other specified bacterial diseases

Baclofen

Section

Medicines for cerebral palsy

Oral > Liquid: 10 mg per 5 mL

Parenteral > Locoregional injections > Intrathecal: 500 µg per mL in ampoule

Oral > Solid > tablet: 10 mg

Indications

Spastic cerebral palsy

Barium sulfate

Section

Diagnostic agents > Radiocontrast media
Oral > Liquid: Aqueous suspension

Indications

Barium sulfate with suspending agents

Beclometasone

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease
Respiratory > Inhalation > aerosol: 50 µg per dose (dipropionate); 250 µg per dose (dipropionatae)

Indications

Asthma

Therapeutic equivalent to [budesonide](#) for

Asthma

Beclometasone + formoterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [budesonide](#) + [formoterol](#) for

Asthma

Bedaquiline

Section

Antituberculosis medicines
Oral > Solid > tablet: 100 mg tablet; 20 mg tablet

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Beinaglutide

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for

Obesity

Bendamustine

Section

Cytotoxic medicines
Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL

Indications

Follicular lymphoma

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Benzathine benzylpenicillin

Section	Indications
Access group antibiotics Parenteral > General injections > IM: 1.2 million IU in vial ($\approx$ 900 mg) powder for injection; 2.4 million IU in vial ($\approx$ 1.8 g) powder for injection	First choice Syphilis Congenital syphilis [children] Other indications Bacterial infection of unspecified site

Benznidazole

Section	Indications
American trypanosomiasis Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg	Chagas disease

Benzoic acid + salicylic acid

Section	Indications
Dermatological medicines > Antifungal medicines Local > Topical > Cream: 6% + 3% Local > Topical > Ointment: 6% + 3%	Fungal infection of the skin

Benzoyl peroxide

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation Local > Topical > Cream: 5% Local > Topical > Lotion: 5%	Acne

Benzyl benzoate

Section	Indications
Dermatological medicines > Scabicides and pediculicides Local > Topical > Lotion: 25%	Pthiriasis Pediculosis corporis Pediculosis capitis Scabies

Benzylpenicillin

Section

Access group antibiotics

Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)

Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)

Medicines for bacterial central nervous system infections

Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)

Indications

First choice

Congenital syphilis [children]

Syphilis

co-prescribed with gentamicin

Sepsis without septic shock

co-prescribed with gentamicin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with gentamicin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Second choice

Bacterial meningitis

Other indications

Bacterial infection of unspecified site

Second choice

Bacterial meningitis

Beractant

Section

Medicines administered to the neonate [c]

Respiratory > Suspension: 25 mg per mL for intratracheal instillation

Indications

Respiratory distress syndrome of newborn

Betamethasone

Section

Dermatological medicines > Anti-inflammatory and antipruritic medicines

Local > Topical > Cream: 0.1% (as valerate)

Local > Topical > Ointment: 0.1% (as valerate)

Indications

Pruritus due to skin disorder

Psoriasis of unspecified type

Dermatitis or eczema

Lichen planus

Bevacizumab

Section

Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

Parenteral > Locoregional injections > Intravitreal: 25 mg per mL

Immunomodulators

Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion

Indications

Age related macular degeneration

Hepatocellular carcinoma of liver

Bicalutamide

Section

Hormones and antihormones

Oral > Solid: 50 mg

Indications

Malignant neoplasms of prostate

Binimetinib

Section

Targeted therapies

Indications

Therapeutic equivalent to [trametinib](#) for

Other specified melanoma of skin

Biperiden

Section

Medicines for parkinsonism

Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)

Oral > Solid: 2 mg tablet (hydrochloride)

Indications

Parkinson disease

Bisacodyl

Section

Laxatives

Indications

Therapeutic equivalent to [senna](#) for

Constipation

Bisoprolol

Section	Indications
Antianginal medicines Oral > Solid: 1.25 mg; 5 mg	Angina pectoris
Medicines used in heart failure Oral > Solid: 1.25 mg; 5 mg	Heart failure
Antihypertensive medicines Oral > Solid: 1.25 mg; 5 mg	Essential hypertension
Antiarrhythmic medicines Oral > Solid: 1.25 mg; 5 mg	Cardiac arrhythmia
Medicines for migraine prophylaxis Oral > Solid: 1.25 mg; 5 mg	Migraine

Bleomycin

Section	Indications
Cytotoxic medicines Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)	Germ cell tumour of testis
	Kaposi sarcoma of unspecified primary site
	Hodgkin lymphoma
	Other specified malignant neoplasms of the ovary
	Unspecified malignant neoplasms of ill-defined or unspecified sites

Blinatumomab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 35 µg in vial; 38.5 µg in vial	B lymphoblastic leukaemia or lymphoma, not elsewhere classified

Bortezomib

Section	Indications
Targeted therapies Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection	Plasma cell myeloma

Brexpiprazole

Section

Medicines for depressive disorders

Oral > Solid > tablet: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg

Indications

Depressive disorders

Bromocriptine

Section

Antiseizure medicines

Oral > Solid: 2.5 mg; 5 mg

Medicines for disorders of the pituitary hormone system

Indications

Parkinson disease

Therapeutic equivalent to [cabergoline](#) for

Other specified benign neoplasm of endocrine glands

Budesonide

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Respiratory > Inhalation > powder: 100 µg per actuation in dry powder inhaler; 200 µg per actuation in dry powder inhaler

Respiratory > Inhalation > suspension: 100 µg per actuation in pressurized metered dose inhaler; 200 µg per actuation in pressurized metered dose inhaler

Ear, nose and throat medicines [c]

Local > Nasal > Spray: 32 µg per actuation; 64 µg per actuation

Indications

Asthma

Allergic rhinitis

Budesonide + formoterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Respiratory > Inhalation > powder: 100 µg + 6 µg per dose actuation in dry powder inhaler; 200 µg + 6 µg per dose actuation in dry powder inhaler

Indications

Asthma

Budesonide + salmeterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [budesonide + formoterol](#) for

Asthma

Bumetanide

Section	Indications
Medicines used in heart failure	Therapeutic equivalent to furosemide for Heart failure
Diuretics	Therapeutic equivalent to furosemide for Anuria or oliguria Therapeutic equivalent to furosemide for Oedema

Bupivacaine

Section	Indications
Local anaesthetics Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 8% glucose solution Parenteral > General injections > unspecified: 0.25% (hydrochloride); 0.5% (hydrochloride)	Local anaesthetics

Buprenorphine

Section	Indications
Medicines for opioid use disorders	Therapeutic equivalent to methadone for Opioid dependence

Bupropion

Section	Indications
Medicines for nicotine use disorders Oral > Solid: 150 mg sustained-release (hydrochloride)	Nicotine dependence

C1 esterase inhibitor

Section	Indications
Plasma-derived medicines Parenteral > General injections > IV: 500 IU in vial powder for injection	Hereditary angioedema

Cabergoline

Section	Indications
Medicines for disorders of the pituitary hormone system Oral > Solid > tablet: 0.5 mg; 1 mg	Other specified benign neoplasm of endocrine glands
Antiseizure medicines Oral > Solid > tablet: 0.5 mg	Parkinson disease

Caffeine citrate

Section	Indications
Medicines administered to the neonate [c] Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL) Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)	Apnoea of newborn

Calamine

Section	Indications
Dermatological medicines > Anti-inflammatory and antipruritic medicines Local > Topical > Lotion:	Pruritus

Calcipotriol

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation Local > Topical > Cream: 50 µg per mL (0.005%) Local > Topical > Lotion: 50 µg per mL (0.005%) Local > Topical > Ointment: 50 µg per mL (0.005%)	Psoriasis of unspecified type

Calcitriol

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation	Therapeutic equivalent to calcipotriol for Psoriasis of unspecified type
Medicines for endocrine disorders Oral > Solid > capsule: 0.25 µg; 0.5 µg	Chronic kidney disease, stage unspecified Disorders of vitamin D metabolism or transport

Calcium

Section

Vitamins and minerals

Oral > Solid: 500 mg (elemental calcium)

Indications

Calcium deficiency

Calcium folinate (leucovorin calcium)

Section

Cytotoxic medicines

Oral > Solid: 15 mg tablet

Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule

Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule

Oral > Solid > tablet: 15 mg; 5 mg; 25 mg

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant trophoblastic neoplasms of placenta

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of rectum

Malignant neoplasms of colon

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasm metastasis in large intestine

Calcium gluconate

Section

Vitamins and minerals

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule or vial (10%)

Indications

Tetany due to acute calcium deficiency

Hypermagnesaemia

Canagliflozin

Section

Oral hypoglycaemic agents

Indications

Therapeutic equivalent to empagliflozin for

Type 2 diabetes mellitus

Capecitabine

Section

Cytotoxic medicines

Oral > Solid > tablet: 150 mg; 500 mg

Indications

Other specified malignant neoplasms of breast

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of rectum

Malignant neoplasms of colon

Capreomycin

Section

Antituberculosis medicines

Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Captopril

Section

Medicines used in heart failure

Oral > Solid: 25 mg

Indications

Heart failure

Carbachol

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

Indications

Therapeutic equivalent to pilocarpine for

Acute angle closure with pupillary block

Therapeutic equivalent to pilocarpine for

Ocular hypertension

Therapeutic equivalent to pilocarpine for

Primary open-angle glaucoma

Carbamazepine

Section	Indications
Medicines for bipolar disorders Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 400 mg	Bipolar or related disorders
Antiseizure medicines Oral > Liquid: 100 mg per 5 mL Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)	Epilepsy or seizures
Medicines for neurological disorders Oral > Liquid: 100 mg per 5 mL Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored) Oral > Solid > capsule: 100 mg (extended-release); 200 mg (extended-release); 300 mg (extended-release)	Trigeminal neuralgia

Carbetocin

Section	Indications
Uterotonics Parenteral > General injections > IV: 100 µg per mL (heat stable)	Postpartum haemorrhage

Carbimazole

Section	Indications
Thyroid hormones and antithyroid medicines	Therapeutic equivalent to methimazole for Thyrotoxicosis

Carboplatin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL

Indications

Other specified gliomas of brain

Other specified carcinomas of ovary

Retinoblastoma

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of nasopharynx

Malignant neoplasms of kidney, except renal pelvis

Malignant neoplasms of breast

Osteosarcoma of bone and articular cartilage of unspecified sites

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx

Malignant neoplasms of hypopharynx

Malignant neoplasms of nasopharynx

Malignant neoplasms of oropharynx

Malignant neoplasms of cervix uteri

Carmellose

Section

Ophthalmological preparations

Indications

Therapeutic equivalent to hypromellose for

Keratoconjunctivitis sicca

Carvedilol

Section	Indications
Antianginal medicines	Therapeutic equivalent to bisoprolol for Angina pectoris
Medicines used in heart failure	Therapeutic equivalent to bisoprolol for Heart failure
Antihypertensive medicines	Therapeutic equivalent to bisoprolol for Essential hypertension
Antiarrhythmic medicines	Therapeutic equivalent to bisoprolol for Cardiac arrhythmia

Caspofungin

Section	Indications
Antifungal medicines	Therapeutic equivalent to micafungin for Systemic or invasive candidosis

Cefalexin

Section	Indications
Access group antibiotics Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid Oral > Solid: 250 mg (as monohydrate) Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate) Oral > Solid > dispersible tablet: 125 mg; 250 mg	First choice Bacterial cellulitis, erysipelas or lymphangitis Second choice Acute pharyngitis Chronic obstructive pulmonary disease with acute exacerbation Other indications Bacterial infection of unspecified site

Cefazolin

Section

Access group antibiotics

Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection

Indications

First choice

Other specified prophylactic measures

co-prescribed with metronidazole

Other specified prophylactic measures

Second choice

Osteomyelitis or osteitis

Bacterial infection of joint

Other indications

Surgical site infection

Cefepime

Section

Watch group antibiotics

Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection

Indications

Other specified bacterial diseases

Cefiderocol

Section

Reserve group antibiotics

Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Cefixime

Section

Watch group antibiotics

Oral > Liquid: 100 mg per 5 mL powder for oral liquid

Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)

Indications

Second choice

Infectious gastroenteritis or colitis without specification of infectious agent

co-prescribed with azithromycin

Gonococcal infection

Cefotaxime

Section

Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Medicines for bacterial central nervous system infections

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

First choice

Other specified pneumonia (Hospital-acquired pneumonia)

Bacterial meningitis

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with amikacin

Inflammatory and other diseases of prostate (severe)

co-prescribed with amikacin

Acute pyelonephritis (severe)

co-prescribed with clarithromycin

Bacterial pneumonia (Community-acquired pneumonia - severe)

co-prescribed with metronidazole

Peritonitis (severe)

co-prescribed with metronidazole

Peritonitis (mild-moderate)

co-prescribed with metronidazole

Peritoneal abscess (severe)

co-prescribed with metronidazole

Peritoneal abscess (mild-moderate)

Second choice

Osteomyelitis or osteitis

Bacterial infection of joint

Inflammatory and other diseases of prostate (mild to moderate)

Acute pyelonephritis (mild to moderate)

Sepsis without septic shock

Other indications

Bacterial infection of unspecified site

First choice

Bacterial meningitis

Ceftaroline

Section

Reserve group antibiotics

Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection

Indications

Other specified bacterial diseases

Ceftazidime

Section

Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection

Indications

First choice

co-prescribed with [vancomycin](#)

Endophthalmitis

Other indications

[Pseudomonas aeruginosa](#) resistant to other antibiotic

Ceftazidime + avibactam

Section

Reserve group antibiotics

Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#)

[Carbapenem resistant Enterobacterales](#)

Ceftolozane + tazobactam

Section

Reserve group antibiotics

Parenteral > General injections > IV: 1 g + 0.5 g powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#)

Ceftriaxone

Section

Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

First choice

[Typhoid fever](#)

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#)

[Paratyphoid fever](#)

[Other specified pneumonia \(Hospital-acquired pneumonia\)](#)

[Bacterial meningitis](#)

co-prescribed with [amikacin](#)

[Acute pyelonephritis \(severe\)](#)

co-prescribed with [amikacin](#)

Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 2 g in vial; 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Medicines for bacterial central nervous system infections

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Inflammatory and other diseases of prostate (severe)

co-prescribed with [azithromycin](#)

Gonococcal infection

co-prescribed with [clarithromycin](#)

Bacterial pneumonia (Community-acquired pneumonia - severe)

co-prescribed with [metronidazole](#)

Necrotising fasciitis

co-prescribed with [metronidazole](#)

Peritonitis (mild-moderate)

co-prescribed with [metronidazole](#)

Peritonitis (severe)

co-prescribed with [metronidazole](#)

Peritoneal abscess (mild-moderate)

co-prescribed with [metronidazole](#)

Peritoneal abscess (severe)

co-prescribed with [vancomycin](#)

Endophthalmitis

Second choice

Bacterial infection of joint

Osteomyelitis or osteitis

Infectious gastroenteritis or colitis without specification of infectious agent

Sepsis without septic shock

Inflammatory and other diseases of prostate (mild to moderate)

Acute pyelonephritis (mild to moderate)

Other indications

Bacterial infection of unspecified site

First choice

Bacterial meningitis

Cefuroxime

Section

Watch group antibiotics

Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

Indications

Second choice

Other specified prophylactic measures

Cemiplimab

Section

Immunomodulators

Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion

Indications

Therapeutic equivalent to pembrolizumab for

Other specified malignant neoplasms of bronchus or lung

Therapeutic equivalent to pembrolizumab for

Adenocarcinoma of stomach

Other specified malignant neoplasms of bronchus or lung

Certolizumab pegol

Section

Immunomodulators for non-malignant disease

Medicines for juvenile joint diseases

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to adalimumab for

Axial spondyloarthritis

Therapeutic equivalent to adalimumab for

Crohn disease site

Therapeutic equivalent to adalimumab for

Rheumatoid arthritis

Therapeutic equivalent to adalimumab for

Juvenile idiopathic arthritis

Therapeutic equivalent to adalimumab for

Psoriasis of unspecified type

Cetirizine

Section

Antiallergics and medicines used in anaphylaxis

Indications

Therapeutic equivalent to loratadine for

Allergic or hypersensitivity conditions of unspecified type

Chlorambucil

Section	Indications
Cytotoxic medicines Oral > Solid: 2 mg tablet	Unspecified malignant neoplasms of ill-defined or unspecified sites Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Chloramphenicol

Section	Indications
Access group antibiotics Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate) Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection Oral > Liquid: 150 mg per 5 mL (as palmitate) Oral > Solid: 250 mg capsule	Second choice Bacterial meningitis Other indications Bacterial infection of unspecified site
Medicines for bacterial central nervous system infections Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate) Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection	Second choice Bacterial meningitis

Chlorhexidine

Section	Indications
Medicines administered to the neonate [c] Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine) Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)	Omphalitis of newborn
Antiseptics Local > Topical > Solution: 5% (digluconate) for dilution	Chlorhexidine

Chlorine base compound

Section	Indications
Disinfectants Local > Topical > Powder: 0.1% available chlorine for solution Local > Topical > Liquid: 0.1% available chlorine for solution Local > Topical > Solid: 0.1% available chlorine for solution	Disinfectant, not elsewhere classified

Chloroquine

Section	Indications
Antimalarial medicines > For chemoprevention Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate) Oral > Solid: 150 mg tablet (as phosphate or sulfate)	Malaria due to Plasmodium falciparum
Antimalarial medicines > For curative treatment Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate) Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate) Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)	Malaria due to Plasmodium falciparum
Disease-modifying anti-rheumatic drugs (DMARDs) Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)	Rheumatoid arthritis
Antimalarial medicines > Medicines for curative treatment Oral > Liquid: 50 mg per 5 mL (base) Oral > Solid > tablet: 150 mg (base)	Malaria due to Plasmodium vivax
Antimalarial medicines > Medicines for chemoprevention Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate) Oral > Solid: 150 mg tablet (as phosphate or sulfate)	Malaria due to Plasmodium ovale Malaria due to Plasmodium malariae Malaria due to Plasmodium vivax
Antimalarial medicines > Medicines for chemoprophylaxis in travellers Oral > Liquid: 50 mg per 5 mL (base) Oral > Solid > tablet: 150 mg (base)	Malaria due to Plasmodium vivax

Chlorothiazide

Section	Indications
Antihypertensive medicines	Therapeutic equivalent to hydrochlorothiazide for Essential hypertension
Medicines used in heart failure	Therapeutic equivalent to hydrochlorothiazide for Heart failure

Chloroxylonol

Section	Indications
Disinfectants Local > Topical > Solution: 4.8%	Phenol disinfectant, not elsewhere classified

Chlorpromazine

Section

Medicines for psychotic disorders

Oral > Liquid: 25 mg per 5 mL (hydrochloride)

Oral > Solid: 100 mg (hydrochloride)

Oral > Solid: 100 mg (hydrochloride); 10 mg (hydrochloride); 25 mg (hydrochloride); 50 mg (hydrochloride)

Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (hydrochloride)

Indications

Therapeutic equivalent to **haloperidol** for

Schizophrenia or other primary psychotic disorders

Schizophrenia or other primary psychotic disorders

Chlortalidone

Section

Antihypertensive medicines

Medicines used in heart failure

Indications

Therapeutic equivalent to **hydrochlorothiazide** for

Essential hypertension

Therapeutic equivalent to **hydrochlorothiazide** for

Heart failure

Chlortetracycline

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to **tetracycline** for

Other specified conjunctivitis

Therapeutic equivalent to **tetracycline** for

Infectious keratitis

Therapeutic equivalent to **tetracycline** for

Infectious blepharitis

Therapeutic equivalent to **tetracycline** for

Trachoma

Cholera vaccine

Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against cholera alone

Ciclesonide

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to budesonide for

Asthma

Ciclopirox

Section

Dermatological medicines > Antifungal medicines

Local > Topical > Solution: 80 mg per g (as hydroxypropyl chitosan)

Indications

Onychomycosis

Ciclosporin

Section

Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule
concentrate for injection

Oral > Liquid: 100 mg per mL

Oral > Solid > capsule: 25 mg

Indications

Failure or rejection of transplanted organs or tissues

Cimetidine

Section

Antiulcer medicines

Oral > Solid: 200 mg

Parenteral > General injections > unspecified: 200 mg in 2 mL ampoule

Indications

Peptic ulcer, site unspecified

Gastro-oesophageal reflux disease

Ciprofloxacin

Section

Watch group antibiotics

Parenteral > General injections > IV: 2 mg per mL (as hyclate)

Oral > Liquid: 250 mg per 5 mL (anhydrous)

Oral > Solid: 250 mg (as hydrochloride)

Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)

Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)

Ear, nose and throat medicines [c]

Local > Otological > drops: 0.3% (as hydrochloride)

Indications

First choice

Neutropenia (low-risk)

Inflammatory and other diseases of prostate (mild to moderate)

Typhoid fever

Paratyphoid fever

Infectious gastroenteritis or colitis without specification of infectious agent

Acute pyelonephritis (mild to moderate)

Second choice

Cholera

Cholera [children]

co-prescribed with metronidazole

Peritoneal abscess (mild-moderate)

co-prescribed with metronidazole

Peritonitis (mild-moderate)

Other indications

Bacterial infection of unspecified site

Infectious diseases of external ear

Cisplatin

Section	Indications
Cytotoxic medicines Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL	Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Germ cell tumour of testis Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx Malignant neoplasms of hypopharynx Malignant neoplasms of nasopharynx Malignant neoplasms of oropharynx Malignant neoplasms of cervix uteri

Cladribine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial	Langerhans cell histiocytosis
Medicines for multiple sclerosis Oral > Solid > tablet: 10 mg	Multiple sclerosis

Clarithromycin

Section

Watch group antibiotics

Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid

Parenteral > General injections > unspecified: 500 mg in vial powder for injection

Oral > Solid > dosage form: 500 mg; 250 mg

Oral > Solid > dosage form: 500 mg

Indications

First choice

co-prescribed with [cefotaxime](#)

Bacterial pneumonia (Community-acquired pneumonia - severe)

co-prescribed with [ceftriaxone](#)

Bacterial pneumonia (Community-acquired pneumonia - severe)

Second choice

Acute pharyngitis

co-prescribed with [amoxicillin + clavulanic acid](#)

Bacterial pneumonia (Community-acquired pneumonia - severe)

Other indications

Helicobacter pylori associated gastric ulcer

Clindamycin

Section

Access group antibiotics

Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)

Oral > Solid: 150 mg (as hydrochloride) capsule

Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection

Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)

Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)

Oral > Solid: 150 mg (as hydrochloride)

Indications

First choice

co-prescribed with [piperacillin + tazobactam](#)

Necrotising fasciitis

Second choice

Osteomyelitis or osteitis

Bacterial infection of joint

Other indications

Bacterial infection of unspecified site

Clofazimine

Section

Antileprosy medicines

Oral > Solid > dosage form: 100 mg; 50 mg

Antituberculosis medicines

Oral > Solid > dosage form: 100 mg; 50 mg

Indications

Leprosy

Multi-drug resistant Mycobacterium tuberculosis

Clomifene

Section

Ovulation inducers

Oral > Solid: 50 mg (citrate)

Indications

Female infertility without specification whether primary or secondary

Clomipramine

Section

Medicines for obsessive compulsive disorders

Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)

Indications

Obsessive-compulsive disorder

Clonazepam

Section

Antiseizure medicines

Oral > Solid: 500 µg

Indications

Generalised myoclonic seizure

Clopidogrel

Section

Anti-platelet medicines

Oral > Solid: 75 mg; 300 mg

Indications

Acute ischaemic heart disease

Presence of coronary angioplasty implant or graft

Clotrimazole

Section

Antifungal medicines

Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet

Indications

Vulvovaginal candidosis

Cloxacillin

Section

Access group antibiotics

Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid

Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule

Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection

Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid

Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection

Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)

Indications

First choice

Bacterial infection of joint

Osteomyelitis or osteitis

Bacterial cellulitis, erysipelas or lymphangitis

Second choice

co-prescribed with amikacin

Sepsis without septic shock

Other indications

Bacterial infection of unspecified site

Clozapine

Section

Medicines for psychotic disorders

Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg

Indications

Schizophrenia or other primary psychotic disorders

Coagulation factor IX complex

Section

Coagulation factors

Indications

Therapeutic equivalent to coagulation factor IX, plasma-derived for

Coagulation defects, purpura or other haemorrhagic or related conditions

Therapeutic equivalent to coagulation factor IX, plasma-derived for

Haemophilia B

Coagulation factor IX, plasma-derived

Section

Coagulation factors

Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection

Indications

Coagulation defects, purpura or other haemorrhagic or related conditions

Haemophilia B

Coagulation factor IX, recombinant

Section

Coagulation factors

Parenteral > General injections > IV: 250 IU per mL in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection

Indications

Haemophilia B

Coagulation factor VIII, plasma-derived

Section

Coagulation factors

Parenteral > General injections > IV: 250 IU in vial powder for injection; 500 IU in vial powder for injection; 1000 IU in vial powder for injection

Indications

Haemophilia A

Coagulation factor VIII, recombinant

Section

Coagulation factors

Parenteral > General injections > IV: 250 IU in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection

Indications

Haemophilia A

Coal tar

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Local > Topical > Solution: 5%

Indications

Psoriasis of unspecified type

Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Cobimetinib

Section

Targeted therapies

Indications

Therapeutic equivalent to trametinib for

Other specified melanoma of skin

Codeine

Section

Opioid analgesics

Oral > Solid: 30 mg tablet (codeine phosphate)

Antitussives

Oral > Solid: 10 mg tablet (codeine phosphate)

Medicines for diarrhoea

Oral > Solid: 30 mg tablet (codeine phosphate)

Indications

Pain

Cough

Diarrhoea

Colchicine

Section

Medicines used to treat gout

Oral > Solid: 0.5 mg

Indications

Gout

Colecalciferol

Section

Vitamins and minerals

Oral > Liquid: 400 IU per mL

Oral > Solid: 400 IU; 1000 IU

Indications

Calcium deficiency

Vitamin D deficiency

Therapeutic equivalent to ergocalciferol for

Vitamin D deficiency

Therapeutic equivalent to ergocalciferol for

Calcium deficiency

Colistin (injection)

Section

Reserve group antibiotics

Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium)

Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium) (equivalent to 34 mg colistin base activity)

Indications

Other specified bacterial diseases

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Compound sodium lactate solution

Section

Solutions correcting water, electrolyte and acid-base disturbances > Parenteral

Parenteral > General injections > IV: injectable solution

Indications

Other specified disorders of fluid, electrolyte or acid-base balance

Hypovolaemic shock

Condoms

Section

Barrier methods

-

Indications

Contact with health services for contraceptive management

Copper-containing intrauterine device

Section

Intrauterine devices

-

Indications

Contact with health services for insertion of contraceptive device

Crizotinib

Section

Targeted therapies

Oral > Solid: 200 mg; 250 mg

Oral > Solid > capsule: 200 mg; 250 mg

Indications

Other specified malignant neoplasms of bronchus or lung

Anaplastic large cell lymphoma, ALK-positive

Cryoprecipitate (not pathogen-reduced)

Section	Indications
Blood and blood components	Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for Obstetric haemorrhage Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for Haemophilia A Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for Von Willebrand disease

Cryoprecipitate (pathogen-reduced)

Section	Indications
Blood and blood components Injection: frozen liquid in bag or lyophilized powder in vial containing: > 50 IU Factor VIII > 100 IU vWF > 140 mg clottable fibrinogen per unit	Coagulation defects, purpura or other haemorrhagic or related conditions Obstetric haemorrhage Haemophilia A Von Willebrand disease

Cyanocobalamin

Section	Indications
Antianaemia medicines .	Anaemias or other erythrocyte disorders

Cyclizine

Section	Indications
Medicines for other common symptoms in palliative care Parenteral > General injections > unspecified: 50 mg per mL (lactate) Oral > Solid > tablet: 50 mg (hydrochloride)	Palliative care

Cyclopentolate

Section	Indications
Diagnostic agents > Ophthalmic medicines	Therapeutic equivalent to tropicamide for Cycloplegic drug
Ophthalmological preparations > Mydriatics	Therapeutic equivalent to atropine for Anterior uveitis

Cyclophosphamide

Section	Indications
Cytotoxic medicines Oral > Solid: 25 mg tablet Parenteral > General injections > unspecified: 500 mg in vial powder for injection Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection Oral > Solid > dosage form: 25 mg; 50 mg	Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified malignant neoplasms of breast Malignant trophoblastic neoplasms of placenta Follicular lymphoma Malignant neoplasms of breast Rhabdomyosarcoma primary site Hodgkin lymphoma Plasma cell myeloma Other specified gliomas of brain Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Cycloserine

Section	Indications
Antituberculosis medicines Oral > Solid > dosage form: 250 mg; 125 mg	Multi-drug resistant Mycobacterium tuberculosis

Cytarabine

Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 100 mg in vial powder for injection

Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Myeloid leukaemia

Burkitt lymphoma including Burkitt leukaemia

Cytisine (cytisinicline)

Section

Medicines for nicotine use disorders

Oral > Solid > tablet: 1.5 mg

Indications

Nicotine dependence

Dabigatran

Section

Medicines affecting coagulation

Oral > Solid: 110 mg; 150 mg

Indications

Venous thromboembolism

Other specified atrial fibrillation

Dabrafenib

Section

Targeted therapies

Oral > Solid: 50 mg; 75 mg

Indications

Other specified melanoma of skin

Dacarbazine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection

Indications

Hodgkin lymphoma

Daclatasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 30 mg (as dihydrochloride); 60 mg (as dihydrochloride)	Chronic hepatitis C

Daclatasvir + sofosbuvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 60 mg (as dihydrochloride) + 400 mg	Chronic hepatitis C

Dactinomycin

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 500 µg in vial powder for injection	Malignant trophoblastic neoplasms of placenta Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site Ewing sarcoma of bone and articular cartilage of unspecified sites

Dalteparin

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism

Dapagliflozin

Section	Indications
Oral hypoglycaemic agents	Therapeutic equivalent to empagliflozin for Type 2 diabetes mellitus

Dapsone

Section	Indications
Antileprosy medicines Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet	Leprosy

Daptomycin

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection	Other specified bacterial diseases

Daratumumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL	Plasma cell myeloma

Darbepoetin alfa

Section	Indications
Antianaemia medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
Supportive medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Drug-induced aplastic anaemia

Darunavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Dasabuvir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 250 mg tablet	Chronic hepatitis C

Dasatinib

Section

Targeted therapies

Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet

Indications

Chronic myeloid leukaemia, not elsewhere classified

Daunorubicin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)

Indications

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Myeloid leukaemia

Deferasirox

Section

Other medicines for haemoglobinopathies

Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg

Oral > Solid > tablet: 90 mg; 180 mg; 360 mg

Indications

Other specified sickle cell disorders or other haemoglobinopathies

Thalassaemias

Therapeutic equivalent to [deferoxamine](#) for

Thalassaemias

Deferiprone

Section

Other medicines for haemoglobinopathies

Indications

Therapeutic equivalent to [deferasirox](#) for

Other specified sickle cell disorders or other haemoglobinopathies

Therapeutic equivalent to [deferasirox](#) for

Thalassaemias

Deferoxamine

Section

Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

Other medicines for haemoglobinopathies

Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

Indications

Harmful effects of drugs, medicaments or biological substances, not elsewhere classified

Other specified sickle cell disorders or other haemoglobinopathies

Thalassaemias

Delafloxacin

Section

Watch group antibiotics

Parenteral > General injections > IV: 300 mg lyophilized powder for injection

Oral > Solid: 450 mg

Indications

Methicillin resistant *Staphylococcus aureus*

Delamanid

Section

Antituberculosis medicines

Oral > Solid > dispersible tablet: 25 mg

Oral > Solid > tablet: 50 mg

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Dengue vaccine

Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Desmopressin

Section

Medicines affecting coagulation

Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)

Local > Nasal > Spray: 150 µg per actuation (acetate)

Indications

Haemophilia A

Von Willebrand disease

Dexamethasone

Section

Other medicines administered to the mother

Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))

Hormones and antihormones

Oral > Liquid: 2 mg per 5 mL

Oral > Solid: 2 mg; 4 mg

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)

Indications

Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy

Anaplastic large cell lymphoma, ALK-negative

Plasma cell myeloma

Burkitt lymphoma including Burkitt leukaemia

Lymphoid leukaemia, not elsewhere classified

Anaplastic large cell lymphoma, ALK-positive

Oral > Solid > tablet: 4 mg (as dexamethasone base)

Oral > Liquid: 2 mg per 5 mL (as sodium phosphate)

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)

Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)

Medicines for other common symptoms in palliative care

Oral > Liquid: 2 mg per 5 mL (as sodium phosphate); 0.5 mg per 5 mL (as sodium phosphate)

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (dexamethasone phosphate (as sodium phosphate) equivalent to 3.3 mg dexamethasone base)

Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base); 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base)

Antiallergics and medicines used in anaphylaxis

Oral > Liquid: 0.5 mg per 5 mL (as sodium phosphate); 2 mg per 5 mL (as sodium phosphate)

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)

Oral > Solid > tablet: 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base); 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)

Antiemetic medicines

Oral > Liquid: 0.5 mg per 5 mL (as sodium phosphate); 2 mg per 5 mL (as sodium phosphate)

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)

Oral > Solid > tablet: 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base); 4 mg (as dexamethasone base); 2 mg (as dexamethasone base)

Palliative care

Allergic or hypersensitivity conditions of unspecified type

Nausea or vomiting

Dextran 40

Section

Plasma substitutes

.

Indications

Hypovolaemia

Dextran 70

Section	Indications
Plasma substitutes Parenteral > General injections > IV: 6% injectable solution	Hypovolaemia

Diaphragms

Section	Indications
Barrier methods -	Contact with health services for contraceptive management

Diazepam

Section	Indications
Medicines for anxiety disorders Oral > Solid: 5 mg (scored); 2 mg (scored)	Anxiety
Antiseizure medicines Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube	Therapeutic equivalent to lorazepam for Status epilepticus Status epilepticus
Medicines for other common symptoms in palliative care Oral > Liquid: 2 mg per 5 mL Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube Parenteral > General injections > unspecified: 5 mg per mL Oral > Solid > tablet: 5 mg (scored); 10 mg (scored); 2 mg (scored)	Palliative care

Diazoxide

Section	Indications
Medicines for hypoglycaemia Oral > Liquid: 50 mg per mL Oral > Solid: 50 mg	Persistent hyperinsulinaemic hypoglycaemia of infancy

Didanosine

Section

[Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors](#)

Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution

Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Diethylcarbamazine

Section

[Antifilarials](#)

Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)

Indications

Lymphatic filariasis

Digitoxin

Section

[Medicines used in heart failure](#)

Parenteral > General injections > IV: 0.2 mg in 1 mL ampoule

Oral > Solid: 50 µg; 100 µg

Indications

Heart failure

Digoxin

Section

[Antiarrhythmic medicines](#)

Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule

Oral > Liquid: 50 µg per mL

Oral > Solid: 62.5 µg; 250 µg

[Medicines used in heart failure](#)

Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule; 100 µg per mL in 1 mL ampoule

Oral > Liquid: 50 µg per mL

Oral > Solid > tablet: 62.5 µg; 250 µg; 125 µg

Indications

Cardiac arrhythmia

Heart failure

Dihydroartemisinin + piperaquine

Section

Antimalarial medicines > Medicines for curative treatment

Oral > Solid > dispersible tablet: 20 mg + 160 mg (phosphate); 40 mg + 320 mg (phosphate)

Oral > Solid > tablet: 40 mg + 320 mg (phosphate); 20 mg + 160 mg (phosphate); 60 mg + 480 (phosphate); 80 mg + 640 mg (phosphate)

Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Dihydroergocryptine mesylate

Section

Antiseizure medicines

Oral > Solid:

Indications

Parkinson disease

Diloxanide

Section

Antiamoebic and anti giardiasis medicines

Oral > Solid: 500 mg (furoate)

Indications

Amoebiasis

Dimercaprol

Section

Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule; 100 mg per mL in 3 mL ampoule

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Dinoprostone (prostaglandin E2)

Section

Medicines administered to the neonate [c]

Parenteral > General injections > IV: 1 mg per mL

Indications

Other specified congenital anomaly of great arteries including arterial duct

Therapeutic equivalent to alprostadil (prostaglandin E1) for

Other specified congenital anomaly of great arteries including arterial duct

Diphtheria antitoxin

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial

Indications

Need for immunization against diphtheria alone

Diphtheria vaccine

Section

[Immunologicals > Vaccines](#)

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against diphtheria alone

Diphtheria-pertussis-tetanus vaccine

Section

[Immunologicals > Vaccines](#)

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against diphtheria-tetanus-pertussis, combined

Diphtheria-tetanus vaccine

Section

[Immunologicals > Vaccines](#)

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against combinations of infectious diseases

Docetaxel

Section

[Cytotoxic medicines](#)

Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL

Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

Malignant neoplasms of prostate

Unspecified malignant neoplasms of ill-defined or unspecified sites

Docusate sodium

Section

[Medicines for other common symptoms in palliative care](#)

Oral > Liquid: 50 mg per 5 mL; 12.5 mg per 5 mL

Oral > Solid > capsule: 100 mg

Indications

Palliative care

Dolasetron

Section	Indications
Medicines for other common symptoms in palliative care	Therapeutic equivalent to ondansetron for Palliative care
Antiemetic medicines	Therapeutic equivalent to ondansetron for Nausea or vomiting

Dolutegravir

Section	Indications
Antiretrovirals > Integrase inhibitors Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Dolutegravir + lamivudine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Donepezil

Section	Indications
Medicines for diseases of the nervous system Oral > Liquid: 1 mg per mL (hydrochloride) Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 5 mg (hydrochloride) (orodispersible); 10 mg (hydrochloride) (orodispersible)	Dementia due to Alzheimer disease

Dopamine

Section	Indications
Medicines used in heart failure Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride)	Heart failure Cardiogenic shock

Dostarlimab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 50 mg per mL in 10 mL vial concentrate for solution for infusion	Other specified malignant neoplasms of corpus uteri

Doxorubicin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)

Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Rhabdomyosarcoma primary site

Malignant neoplasms of breast

Hodgkin lymphoma

Plasma cell myeloma

Follicular lymphoma

Malignant neoplasms of kidney, except renal pelvis

Osteosarcoma of bone and articular cartilage of unspecified sites

Anaplastic large cell lymphoma, ALK-negative

Other specified malignant neoplasms of breast

Anaplastic large cell lymphoma, ALK-positive

Ewing sarcoma of bone and articular cartilage of unspecified sites

Kaposi sarcoma of unspecified primary site

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Diffuse large B-cell lymphoma, not otherwise specified

Doxorubicin (as pegylated liposomal)

Section

Cytotoxic medicines

Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Indications

Kaposi sarcoma of unspecified primary site

Doxycycline

Section

Access group antibiotics

Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)

Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)

Parenteral > General injections > unspecified: 100 mg in vial powder for injection

Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)

Oral > Solid > dispersible tablet: 100 mg (as monohydrate)

Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)

Oral > Solid > dosage form: 100 mg (as hyclate)

Antimalarial medicines > Medicines for chemoprophylaxis in travellers

Oral > Liquid: 50 mg per 5 mL (calcium); 25 mg per 5 mL (monohydrate) powder for oral liquid

Oral > Solid > dispersible tablet: 100 mg (as monohydrate)

Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)

Antimalarial medicines > Medicines for curative treatment

Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)

Antimalarial medicines > Medicines for chemoprevention

Oral > Solid: 100 mg (hydrochloride or hyclate)

Indications

First choice

Chlamydia trachomatis

Cholera

Second choice

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Chronic obstructive pulmonary disease with acute exacerbation

Cholera [children]

Other indications

Bacterial infection of unspecified site

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium falciparum

Dulaglutide

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to semaglutide for

Obesity

Therapeutic equivalent to semaglutide for

Type 2 diabetes mellitus

Durvalumab

Section

Immunomodulators

Parenteral > General injections > IV: 50 mg per mL in 2.4 mL vial concentrate solution for infusion; 50 mg per mL in 10 mL vial concentrate solution for infusion

Indications

Other specified malignant neoplasms of bronchus or lung

Hepatocellular carcinoma of liver

Malignant neoplasms of biliary tract, distal bile duct

Malignant neoplasm of intrahepatic bile ducts

Malignant neoplasms of gallbladder

Malignant neoplasms of proximal biliary tract, cystic duct

Edoxaban

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to dabigatran for

Venous thromboembolism

Therapeutic equivalent to dabigatran for

Other specified atrial fibrillation

Efavirenz

Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
Oral > Solid: 600 mg tablet

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Efavirenz + emtricitabine + tenofovir

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Efavirenz + lamivudine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Therapeutic equivalent to efavirenz + emtricitabine + tenofovir for

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Eflornithine

Section

Medicines for the treatment of 2nd stage African trypanosomiasis

Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)

Indications

Gambiense trypanosomiasis

Elbasvir + grazoprevir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 50 mg + 100 mg

Indications

Chronic hepatitis C

Eletriptan

Section

Medicines for acute migraine attacks

Oral > Solid > tablet: 40 mg

Indications

Therapeutic equivalent to sumatriptan for

Migraine

Elexacaftor + tezacaftor + ivacaftor

Section

Medicines for cystic fibrosis

Oral > Solid > tablet: 50 mg + 25 mg + 37.5 mg; 100 mg + 50 mg + 75 mg

Oral > Solid > granules: 80 mg + 40 mg + 60 mg in sachet; 100 mg + 50 mg + 75 mg in sachet

Indications

Cystic fibrosis

Emicizumab

Section

Medicines affecting coagulation

Parenteral > General injections > SC: 12 mg per 0.4 mL in vial; 30 mg per mL in mL vial; 60 mg per 0.4 mL in vial; 105 mg per 0.7 mL in vial; 150 mg per mL in vial; 300 mg per 2 mL in vial

Indications

Haemophilia A

Empagliflozin

Section

Oral hypoglycaemic agents

Oral > Solid: 10 mg; 25 mg

Indications

Type 2 diabetes mellitus

Emtricitabine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 10 mg per mL

Oral > Solid: 200 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Emtricitabine + rilpivirine + tenofovir alafenamide

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 25 mg + 25 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Emtricitabine + rilpivirine + tenofovir disoproxil fumarate

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Emtricitabine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Contact with or exposure to human immunodeficiency virus

Emtricitabine + tenofovir alafenamide

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Enalapril

Section

Antihypertensive medicines

Oral > Liquid: 1 mg per mL (as hydrogen maleate)

Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)

Medicines used in heart failure

Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)

Indications

Essential hypertension

Heart failure

Encorafenib

Section

Targeted therapies

Indications

Therapeutic equivalent to [dabrafenib](#) for

Other specified melanoma of skin

Enoxaparin

Section

Medicines affecting coagulation

Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule

Indications

Acute ischaemic heart disease

Venous thromboembolism

Entecavir

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 0.05 mg per mL

Oral > Solid: 0.5 mg; 1 mg

Indications

Chronic hepatitis B

Enzalutamide

Section

Hormones and antihormones

Oral > Solid: 40 mg

Indications

Therapeutic equivalent to abiraterone for

Malignant neoplasms of prostate

Malignant neoplasms of prostate

Ephedrine

Section

Local anaesthetics

Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)

Indications

Cardiac complications of anaesthesia during labour or delivery

Epinephrine

Section

Antiarrhythmic medicines

Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)

Ophthalmological preparations > Mydriatics

Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)

Antiallergics and medicines used in anaphylaxis

Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)

Indications

Cardiac arrest

Primary open-angle glaucoma

Asthma

Chronic obstructive pulmonary disease

Anaphylaxis

Epoetin alfa

Section

Antianaemia medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Anaemia due to chronic disease

Supportive medicines

Therapeutic equivalent to erythropoiesis-stimulating agents for

Drug-induced aplastic anaemia

Epoetin beta

Section	Indications
Antianaemia medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
Supportive medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Drug-induced aplastic anaemia

Epoetin theta

Section	Indications
Antianaemia medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease

Eptinezumab

Section	Indications
Medicines for migraine prophylaxis	Therapeutic equivalent to fremanezumab for Chronic migraine

Equine rabies immunoglobulin

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial; 200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial	Rabies

Eravacycline

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 50 mg lyophilized powder for injection	Carbapenem resistant Enterobacterales

Erenumab

Section

Medicines for migraine prophylaxis

Indications

Therapeutic equivalent to [fremanezumab](#) for

Chronic migraine

Ergocalciferol

Section

Vitamins and minerals

Oral > Liquid: 250 µg per mL (10 000 IU per mL)

Oral > Solid: 1.25 mg (50 000 IU)

Indications

Therapeutic equivalent to [colecalfiferol](#) for

Calcium deficiency

Therapeutic equivalent to [colecalfiferol](#) for

Vitamin D deficiency

Vitamin D deficiency

Calcium deficiency

Ergometrine

Section

Uterotonics

Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)

Indications

Postpartum haemorrhage

Erlotinib

Section

Targeted therapies

Oral > Solid: 100 mg; 150 mg

Indications

Other specified malignant neoplasms of bronchus or lung

Erythromycin

Section

Watch group antibiotics

Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)

Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)

Oral > Solid: 250 mg (as stearate or ethylsuccinate)

Indications

Second choice

Therapeutic equivalent to [clarithromycin](#) for

Acute pharyngitis

Other indications

Bacterial infection of unspecified site

Chlamydial conjunctivitis

Gonococcal infection of eye

Ophthalmological preparations > Anti-infective agents

Local > Ophthalmological > Ointment: 0.5%

Erythropoiesis-stimulating agents

Section

Antianaemia medicines

Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe

Supportive medicines

Parenteral > General injections > unspecified: 2000 IU per mL in vial (single-dose); 3000 IU per mL in vial (single-dose); 4000 IU per mL in vial (single-dose); 10000 IU per mL in vial (single-dose); 40000 IU per mL in vial (single-dose); 20000 IU per mL in vial (multiple-dose); 20000 IU per 2 mL in vial (multiple-dose)

Indications

Anaemia due to chronic disease

Drug-induced aplastic anaemia

Estradiol

Section

Estrogens

Oral > Solid > tablet: 0.5 mg; 1 mg; 2 mg

Indications

Gonadotropin deficiency

Hypopituitarism

Turner syndrome

Estradiol cypionate + medroxyprogesterone acetate

Section

Injectable hormonal contraceptives

Parenteral > General injections > IM: 5 mg + 25 mg

Indications

Contact with health services for reasons associated with reproduction

Etanercept

Section

Immunomodulators for non-malignant disease

Medicines for juvenile joint diseases

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Therapeutic equivalent to [adalimumab](#) for

Psoriasis of unspecified type

Ethambutol

Section

Antituberculosis medicines

Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL

Oral > Solid > dispersible tablet: 100 mg

Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)

Indications

Other specified tuberculosis

Tuberculosis

Ethambutol + isoniazid

Section

Antituberculosis medicines

Oral > Solid: 400 mg + 150 mg tablet

Indications

Tuberculosis

Ethambutol + isoniazid + pyrazinamide + rifampicin

Section

Antituberculosis medicines

Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet

Indications

Tuberculosis

Ethambutol + isoniazid + rifampicin

Section

Antituberculosis medicines

Oral > Solid: 275 mg + 75 mg + 150 mg tablet

Indications

Tuberculosis

Ethanol

Section

Antiseptics

Local > Topical > Solution: 70% (denatured)

Indications

Denatured alcohol

Ether

Section

General anaesthetics and oxygen > Inhalational medicines

Respiratory > Inhalation > solution:

Indications

Anaesthetics and therapeutic gases

Ethinylestradiol + etonogestrel

Section

Intravaginal contraceptives

Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg

Indications

Contact with health services for contraceptive management

Ethinylestradiol + levonorgestrel

Section

Oral hormonal contraceptives

Oral > Solid: 50 µg + 250 µg [4]

Oral > Solid: 30 µg + 150 µg

Indications

Contact with health services for postcoital contraception

Contact with health services for contraceptive management

Ethinylestradiol + norethisterone

Section

Oral hormonal contraceptives

Oral > Solid: 35 µg + 1 mg

Indications

Contact with health services for contraceptive management

Ethionamide

Section

Antituberculosis medicines

Oral > Solid > dispersible tablet: 125 mg

Oral > Solid > tablet: 250 mg

Indications

Tuberculous meningitis

Multi-drug resistant Mycobacterium tuberculosis

Ethosuximide

Section	Indications
Antiseizure medicines Oral > Liquid: 250 mg per 5 mL Oral > Solid: 250 mg	Absence seizures, typical

Etonogestrel-releasing implant

Section	Indications
Implantable contraceptives Implant > Subdermal: 68 mg single rod	Contact with health services for insertion of contraceptive device

Etoposide

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule Oral > Solid: 100 mg capsule Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate) Oral > Solid: 100 mg capsule; 50 mg capsule	Unspecified malignant neoplasms of ill-defined or unspecified sites Ewing sarcoma of bone and articular cartilage of unspecified sites Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Germ cell tumour of testis Malignant trophoblastic neoplasms of placenta Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Hodgkin lymphoma Retinoblastoma Anaplastic large cell lymphoma, ALK-positive Anaplastic large cell lymphoma, ALK-negative Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Burkitt lymphoma including Burkitt leukaemia

Everolimus

Section	Indications
Targeted therapies Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg	Other specified gliomas of brain

Exenatide

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to **semaglutide** for

Obesity

Fentanyl

Section

Opioid analgesics

Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour

Oral > Solid: 100 to 800 µg sub-lingual tablet (as citrate); 200 to 1600 µg lozenge (as citrate)

Oral > Other: 200 to 1200 µg buccal film (as citrate)

Indications

Chronic cancer pain

Other specified chronic cancer related pain

Ferrous salt

Section

Antianaemia medicines

Oral > Liquid: 25 mg per mL elemental iron; 9 mg per mL elemental iron

Oral > Solid > tablet: 60 to 65 mg elemental iron

Indications

Iron deficiency anaemia

Ferrous salt + folic acid

Section

Antianaemia medicines

Oral > Solid: 60 mg iron + 2.8 mg

Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg

Indications

Iron deficiency anaemia

Clefts of lip, alveolus or palate

Iron deficiency anaemia

Anencephaly or similar anomalies

Spina bifida

Fexinidazole

Section

Medicines for the treatment of 1st stage African trypanosomiasis

Oral > Solid > tablet: 600 mg

Oral > Solid: 600 mg

Medicines for the treatment of 2nd stage African trypanosomiasis

Oral > Solid > tablet: 600 mg

Oral > Solid: 600 mg

Indications

Rhodesiense trypanosomiasis

Gambiense trypanosomiasis

Rhodesiense trypanosomiasis

Gambiense trypanosomiasis

Fexofenadine

Section

Antiallergics and medicines used in anaphylaxis

Indications

Therapeutic equivalent to loratadine for

Allergic or hypersensitivity conditions of unspecified type

Fifth generation cephalosporins

Section

Reserve group antibiotics

Indications

Other specified bacterial diseases

Filgrastim

Section

Immunomodulators

Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial

Indications

Acquired neutropaenia

Fingolimod

Section

Immunomodulators for non-malignant disease

Oral > Solid: 0.25 mg; 0.5 mg

Indications

Relapsing-remitting multiple sclerosis

Flomoxef

Section

Watch group antibiotics

Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection

Indications

Other specified other antibiotic resistant Enterobacterales

Fluconazole

Section

Antifungal medicines

Parenteral > General injections > IV: 2 mg per mL in vial

Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid

Oral > Solid > capsule: 50 mg

Indications

Cryptococcosis

Candidosis

Flucytosine

Section

Antifungal medicines

Parenteral > General injections > IV: 2.5 g per 250 mL infusion

Oral > Solid: 250 mg capsule

Indications

Cryptococcosis

Fludarabine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection

Oral > Solid: 10 mg tablet (fludarabine phosphate)

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Fludrocortisone

Section

Adrenal hormones and synthetic substitutes

Oral > Liquid: 100 µg per mL

Oral > Solid > tablet: 100 µg (acetate)

Indications

Adrenocortical insufficiency

Flunisolide

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [budesonide](#) for

Asthma

Fluorescein

Section

Diagnostic agents > Ophthalmic medicines

Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)

Indications

Fluorescein

Fluoride

Section

Dental medicines and preparations

Local > Dental > Gel: 2500 to 12500 ppm fluoride (any type)

Local > Dental > Toothpaste, cream or gel: 1000 to 1500 ppm fluoride (any type)

Local > Dental > Mouthrinse: 230 to 900 ppm fluoride (any type)

Local > Dental > Varnish: 22500 ppm fluoride (any type)

Indications

Dental caries

Fluorouracil

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Local > Topical > Ointment: 5%

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule

Parenteral > General injections > IV: 50 mg per mL in vial

Indications

Plantar warts

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasms of nasopharynx

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of breast

Malignant neoplasms of rectum

Malignant neoplasms of colon

Fluoxetine

Section

Medicines for depressive disorders

Oral > Solid: 20 mg (as hydrochloride)

Medicines for other common symptoms in palliative care

Oral > Solid: 20 mg (as hydrochloride)

Medicines for anxiety disorders

Oral > Solid: 20 mg (as hydrochloride)

Medicines for obsessive compulsive disorders

Oral > Solid: 20 mg (as hydrochloride)

Indications

Depressive disorders

Palliative care

Social anxiety disorder

Generalised anxiety disorder

Panic disorder

Obsessive-compulsive disorder

Fluphenazine

Section

Medicines for psychotic disorders

Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthate)

Indications

Schizophrenia or other primary psychotic disorders

Flutamide

Section

Hormones and antihormones

Indications

Therapeutic equivalent to bicalutamide for

Malignant neoplasms of prostate

Fluticasone

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to **budesonide** for

Asthma

Fluticasone + formoterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to **budesonide + formoterol** for

Asthma

Fluticasone furoate + vilanterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to **budesonide + formoterol** for

Asthma

Fluvastatin

Section

Lipid-lowering agents

Indications

Therapeutic equivalent to **simvastatin** for

Mixed hyperlipidaemia

Therapeutic equivalent to **simvastatin** for

Coronary atherosclerosis

Folic acid

Section

Antianaemia medicines

Oral > Solid: 400 µg

Oral > Liquid: 1 mg per mL

Oral > Solid: 1 mg tablet; 5 mg tablet

Indications

Anencephaly or similar anomalies

Spina bifida

Cephalocele

Folate deficiency anaemia

Fomepizole

Section

Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule or vial (sulfate); 1 g per mL in 1.5 mL ampoule or vial (base)

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Fosfomycin (injection)

Section

Reserve group antibiotics

Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection

Indications

Other specified bacterial diseases

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Fourth generation cephalosporins

Section

Watch group antibiotics

.

Indications

Other specified bacterial diseases

Fremanezumab

Section

Medicines for migraine prophylaxis

Parenteral > General injections > SC: 225 mg per 1.5 mL in pre-filled syringe

Indications

Chronic migraine

Fresh-frozen plasma

Section

Blood and blood components

Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis

Fulvestrant

Section

Hormones and antihormones

Parenteral > General injections > IV: 250 mg per 5 mL

Indications

Malignant neoplasms of breast

Furosemide

Section	Indications
Medicines used in heart failure Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL Oral > Solid > tablet: 40 mg; 20 mg	Heart failure
Diuretics Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL Oral > Solid > tablet: 40 mg; 20 mg	Anuria or oliguria Oedema

Gabapentin

Section	Indications
Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs) Oral > Solid: 100 mg; 200 mg; 300 mg; 400 mg; 600 mg; 800 mg	Neuropathic pain

Galcanezumab

Section	Indications
Medicines for migraine prophylaxis	Therapeutic equivalent to fremanezumab for Chronic migraine

Gallamine

Section	Indications
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors Parenteral > General injections > IV: 40 mg per mL in 2 mL ampoule (gallamine triethiodide)	Muscle relaxants

Gatifloxacin

Section	Indications
Antituberculosis medicines Oral > Solid: 200 mg; 400 mg	Multi-drug resistant Mycobacterium tuberculosis

Gefitinib

Section

Targeted therapies

Indications

Therapeutic equivalent to erlotinib for

Other specified malignant neoplasms of bronchus or lung

Gemcitabine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection

Indications

Other specified carcinomas of ovary

Other specified malignant neoplasms of bronchus or lung

Gentamicin

Section

Access group antibiotics

Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

Indications

First choice

Neonatal meningitis

co-prescribed with amoxicillin

Sepsis without septic shock

co-prescribed with amoxicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with ampicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with ampicillin

Sepsis without septic shock

co-prescribed with ampicillin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with ampicillin

Peritoneal abscess (severe)

co-prescribed with ampicillin

Peritonitis (mild-moderate)

co-prescribed with ampicillin

Peritonitis (severe)

co-prescribed with ampicillin

Peritoneal abscess (mild-moderate)

co-prescribed with benzylpenicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with benzylpenicillin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with [benzylpenicillin](#)

[Sepsis without septic shock](#)

Second choice

[Other specified prophylactic measures](#)

[Gonococcal infection](#)

Other indications

[Bacterial infection of unspecified site](#)

[Other specified conjunctivitis](#)

[Infectious blepharitis](#)

First choice

[Neonatal meningitis](#)

[Ophthalmological preparations > Anti-infective agents](#)

Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)

[Medicines for bacterial central nervous system infections](#)

Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

Glass ionomer cement

Section

[Dental medicines and preparations](#)

Local > Dental > Powder + liquid: Single-use capsules: 0.4 g powder + 0.09 mL liquid; Multi-use bottle: powder + liquid

Indications

[Dental caries](#)

Glatiramer acetate

Section

[Medicines for multiple sclerosis](#)

Parenteral > General injections > SC: 20 mg per mL in pre-filled syringe; 40 mg per mL in pre-filled syringe

Parenteral > General injections > SC: 20 mg per mL; 40 mg per mL

Indications

[Multiple sclerosis](#)

[Relapsing-remitting multiple sclerosis](#)

Glecaprevir + pibrentasvir

Section

[Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations](#)

Oral > Solid: 50 mg + 20 mg granules

Oral > Solid > tablet: 100 mg + 40 mg

Indications

[Chronic hepatitis C](#)

Glibenclamide

Section

Oral hypoglycaemic agents

Oral > Solid: 5 mg; 2.5 mg

Indications

Type 2 diabetes mellitus

Gliclazide

Section

Oral hypoglycaemic agents

Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release

Indications

Type 2 diabetes mellitus

Glucagon

Section

Medicines for hypoglycaemia

Parenteral > General injections > unspecified: 1 mg per mL as powder and diluent

Indications

Hypoglycaemia in the context of diabetes

Glucose

Section

Solutions correcting water, electrolyte and acid-base disturbances >

Parenteral

Parenteral > General injections > IV: 5% isotonic; 10% hypertonic

Parenteral > General injections > IV: 50% hypertonic

Indications

Other specified disorders of fluid, electrolyte or acid-base balance

Hypoglycaemia without associated diabetes

Glucose + sodium chloride

Section

Solutions correcting water, electrolyte and acid-base disturbances >

Parenteral

Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na⁺ 30 mmol/L and Cl⁻ 30 mmol/L; 5% + 0.9% (equivalent to Na⁺ 150 mmol/L and Cl⁻ 150 mmol/L); 5% + 0.45% (equivalent to Na⁺ 75 mmol/L and Cl⁻ 75 mmol/L)

Indications

Other specified disorders of fluid, electrolyte or acid-base balance

Glutaral

Section

Disinfectants

Local > Topical > Solution: 2%

Indications

Glutaral nonmedicinal

Glycerol

Section

Dermatological medicines > Moisturizers
Local > Topical > Cream: 15 to 20%

Indications

Atopic eczema

Glyceryl trinitrate

Section

Antianginal medicines
Oral > Solid: 500 µg sublingual tablet

Indications

Angina pectoris

Glycopyrronium

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [tiotropium bromide](#) for

Chronic obstructive pulmonary disease

Golimumab

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Medicines for juvenile joint diseases

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Goserelin

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [leuporelin](#) for

Malignant neoplasms of breast

Therapeutic equivalent to [leuporelin](#) for

Malignant neoplasms of prostate

Granisetron

Section	Indications
Medicines for other common symptoms in palliative care	Therapeutic equivalent to ondansetron for Palliative care
Antiemetic medicines	Therapeutic equivalent to ondansetron for Nausea or vomiting

Griseofulvin

Section	Indications
Antifungal medicines Oral > Liquid: 125 mg per 5 mL Oral > Solid: 125 mg; 250 mg	Dermatophytosis

Haemophilus influenzae type b vaccine

Section	Indications
Immunologicals > Vaccines All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against single bacterial diseases

Haloperidol

Section	Indications
Medicines for other common symptoms in palliative care Oral > Liquid: 2 mg per mL Oral > Solid: 0.5 mg; 2 mg; 5 mg Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule	Palliative care
Medicines for psychotic disorders Parenteral > General injections > IM: 5 mg per mL in ampoule Oral > Solid: 2 mg; 5 mg	Schizophrenia or other primary psychotic disorders

Haloperidol decanoate

Section	Indications
Medicines for psychotic disorders	Therapeutic equivalent to fluphenazine for Schizophrenia or other primary psychotic disorders

Halothane

Section

General anaesthetics and oxygen > Inhalational medicines
Respiratory > Inhalation > liquid:

Indications

Anaesthetics and therapeutic gases

Heparin sodium

Section

Medicines affecting coagulation
Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule or vial; 20000 IU per mL in 1 mL ampoule or vial; 5000 IU per mL in 1 mL ampoule or vial

Indications

Acute ischaemic heart disease

Unstable angina

Venous thromboembolism

Hepatitis A vaccine

Section

Immunologicals > Vaccines
All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against viral hepatitis

Hepatitis B vaccine

Section

Immunologicals > Vaccines
All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against viral hepatitis

Hepatitis E vaccine

Section

Immunologicals > Vaccines
All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against viral hepatitis

Homatropine

Section

Ophthalmological preparations > Mydriatics
Local > Ophthalmological > Solution (eye drops): 2% (hydrobromide)

Indications

Anterior uveitis

Therapeutic equivalent to atropine for

Anterior uveitis

Human papilloma virus (HPV) vaccine

Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Hydralazine

Section

Antihypertensive medicines

Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)

Oral > Solid: 50 mg tablet; 25 mg tablet (hydrochloride)

Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)

Indications

Essential hypertension

Gestational hypertension

Hydrochlorothiazide

Section

Antihypertensive medicines

Oral > Liquid: 50 mg per 5 mL

Oral > Solid: 25 mg; 12.5 mg

Medicines used in heart failure

Oral > Liquid: 50 mg per 5 mL

Oral > Solid: 25 mg

Diuretics

Oral > Solid > dosage form: 25 mg; 12.5 mg

Indications

Essential hypertension

Heart failure

Oedema

Hydrocortisone

Section	Indications
Hormones and antihormones Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)	Unspecified malignant neoplasms of ill-defined or unspecified sites Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia
Ophthalmological preparations > Anti-inflammatory agents Local > Ophthalmological > Ointment: 1% (acetate)	Scleritis Anterior uveitis
Antiallergics and medicines used in anaphylaxis Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)	Anaphylaxis
Anti-inflammatory medicines Local > Rectal > Suppository: 25 mg (acetate) Local > Rectal > Retention enema: 100 mg per 60 mL	Crohn disease site Ulcerative colitis
Dermatological medicines > Anti-inflammatory and antipruritic medicines Local > Topical > Cream: 1% (acetate) Local > Topical > Ointment: 1% (acetate)	Dermatitis or eczema Lichen planus Pruritus due to skin disorder Psoriasis of unspecified type
Adrenal hormones and synthetic substitutes Oral > Solid > tablet: 5 mg; 10 mg; 20 mg Oral > Solid > granules: 0.5 mg in capsule; 1 mg in capsule; 2 mg in capsule; 5 mg in capsule	Adrenocortical insufficiency

Hydromorphone

Section	Indications
Opioid analgesics	Therapeutic equivalent to morphine for Pain

Hydroxocobalamin

Section	Indications
Antianaemia medicines Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)	Megaloblastic anaemia due to vitamin B12 deficiency

Hydroxycarbamide (hydroxyurea)

Section	Indications
Cytotoxic medicines Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg	Squamous cell carcinoma of oropharynx Chronic myeloid leukaemia, not elsewhere classified
Other medicines for haemoglobinopathies Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg	Other specified sickle cell disorders or other haemoglobinopathies

Hydroxychloroquine

Section	Indications
Antimalarial medicines > For chemoprevention	Therapeutic equivalent to chloroquine for Malaria due to Plasmodium falciparum
Disease-modifying anti-rheumatic drugs (DMARDs) Oral > Solid: 200 mg (as sulfate)	Systemic lupus erythematosus Cutaneous lupus erythematosus of unspecified type

Hyoscine butylbromide

Section	Indications
Medicines for other common symptoms in palliative care Parenteral > General injections > unspecified: 20 mg per mL injection	Palliative care

Hyoscine hydrobromide

Section	Indications
Medicines for other common symptoms in palliative care Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch Parenteral > General injections > unspecified: 400 µg per mL injection; 600 µg per mL injection	Palliative care

Hypochlorous acid

Section	Indications
Disinfectants Solution (aqueous): containing hypochlorous acid $\geq$ 150 parts per million	Disinfectant, not elsewhere classified
Antiseptics Solution (aqueous): containing hypochlorous acid $\geq$ 150 parts per million	Hypochlorite

Hypromellose

Section

Ophthalmological preparations

Local > Ophthalmological > Solution (eye drops): 0.3%

Indications

Keratoconjunctivitis sicca

Ibrutinib

Section

Targeted therapies

Oral > Solid: 140 mg

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Ibuprofen

Section

Medicines administered to the neonate [c]

Parenteral > General injections > IV: 5 mg per mL

Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)

Oral > Liquid: 200 mg per 5 mL; 100 mg per 5 mL

Oral > Solid > tablet: 200 mg; 400 mg; 600 mg

Medicines for acute migraine attacks

Oral > Liquid: 100 mg per 5 mL; 200 mg per 5 mL

Oral > Solid > tablet: 200 mg; 400 mg

Indications

Patent arterial duct

Pain

Migraine

Idoxuridine

Section

Ophthalmological preparations > Anti-infective agents

Local > Ophthalmological > Solution (eye drops): 0.1%

Local > Ophthalmological > Ointment: 0.2%

Indications

Herpes simplex keratitis

Ifosfamide

Section

Cytotoxic medicines

Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection

Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Osteosarcoma of bone and articular cartilage of unspecified sites

Rhabdomyosarcoma primary site

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Burkitt lymphoma including Burkitt leukaemia

Imatinib

Section

Targeted therapies

Oral > Solid: 100 mg; 400 mg

Indications

B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1

Gastrointestinal stromal tumour of unspecified gastrointestinal sites

Chronic myeloid leukaemia, not elsewhere classified

Imipenem + cilastatin

Section

Watch group antibiotics

Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection

Antituberculosis medicines

Indications

Second choice

Therapeutic equivalent to [meropenem](#) for

Neutropenia (high-risk)

Therapeutic equivalent to [meropenem](#) for

Peritoneal abscess (severe)

Therapeutic equivalent to [meropenem](#) for

Peritonitis (severe)

Other indications

Pseudomonas aeruginosa resistant to other antibiotic

Antibiotic resistant Acinetobacter baumannii

Therapeutic equivalent to [meropenem](#) for

Multi-drug resistant Mycobacterium tuberculosis

Imipenem + cilastatin + relebactam

Section

Reserve group antibiotics

Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection

Parenteral > General injections > IV: 500 mg (as monohydrate) + 500 mg (as sodium) + 250 mg (as monohydrate) powder for injection

Indications

Other specified other antibiotic resistant Enterobacterales

Carbapenem resistant Enterobacterales

Carbapenem-resistant Pseudomonas aeruginosa

Indapamide

Section

Antihypertensive medicines

Therapeutic equivalent to [hydrochlorothiazide](#) for

Essential hypertension

Medicines used in heart failure

Therapeutic equivalent to [hydrochlorothiazide](#) for

Heart failure

Indinavir

Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 400 mg (as sulfate)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Indometacin

Section

Medicines administered to the neonate [c]

Indications

Therapeutic equivalent to [ibuprofen](#) for

Patent arterial duct

Infliximab

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Medicines for juvenile joint diseases

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Therapeutic equivalent to [adalimumab](#) for

Psoriasis of unspecified type

Influenza vaccine (seasonal)

Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against influenza

Insulin (analogue, long-acting)

Section	Indications
Insulins Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution; 100 IU per mL in 10 mL vial solution	Type 2 diabetes mellitus Type 1 diabetes mellitus

Insulin (analogue, rapid-acting)

Section	Indications
Insulins Parenteral > General injections > SC: 100 IU per 1 mL in 10 mL vial; 100 IU per 1 mL in 3 mL cartridge; 100 IU per 1 mL in 3 mL pre-filled pen	Type 1 diabetes mellitus Type 2 diabetes mellitus

Insulin (human, intermediate-acting)

Section	Indications
Insulins Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin	Type 2 diabetes mellitus Type 1 diabetes mellitus

Insulin (human, short-acting)

Section	Indications
Insulins Parenteral > General injections > SC: 40 IU per mL in 10 mL vial solution; 100 IU per mL in 10 mL vial solution; 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution	Type 2 diabetes mellitus Type 1 diabetes mellitus

Insulin analogues

Section	Indications
Insulins Not specified	Type 1 diabetes mellitus Type 2 diabetes mellitus

Insulin aspart

Section

Insulins

Parenteral > General injections > SC: 100 IU per mL in 110 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

Indications

Therapeutic equivalent to insulin (analogue, rapid-acting) for

Type 1 diabetes mellitus

Therapeutic equivalent to insulin (analogue, rapid-acting) for

Type 2 diabetes mellitus

Insulin degludec

Section

Insulins

Parenteral > General injections > SC: 100 units per mL

Indications

Therapeutic equivalent to insulin glargine for

Type 1 diabetes mellitus

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 2 diabetes mellitus

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 1 diabetes mellitus

Insulin detemir

Section

Insulins

Indications

Therapeutic equivalent to insulin glargine for

Type 1 diabetes mellitus

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 2 diabetes mellitus

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 1 diabetes mellitus

Insulin glargine

Section

Insulins

Parenteral > General injections > SC: 100 units per mL

Indications

Type 1 diabetes mellitus

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 2 diabetes mellitus

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 1 diabetes mellitus

Insulin glulisine

Section

Insulins

Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

Indications

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

Type 1 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

Type 2 diabetes mellitus

Insulin lispro

Section

Insulins

Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

Indications

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

Type 1 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

Type 2 diabetes mellitus

Intraperitoneal dialysis solution

Section

Peritoneal dialysis solution

Solution: of appropriate composition in accordance with local clinical guidelines.

Indications

Care involving peritoneal dialysis

Iodine

Section

Antiseptics

Vitamins and minerals

Parenteral > General injections > IM: 480 mg per mL in 10 mL ampoule or vial iodized oil (oral or injectable)

Indications

Therapeutic equivalent to [povidone iodine](#) for

Povidone iodine

Iodine deficiency

Iodine + potassium iodide (Lugol's solution)

Section

Thyroid hormones and antithyroid medicines

Oral > Liquid: 5% w/v + 10% w/v (aqueous)

Indications

Thyrotoxicosis

Iohexol

Section

Diagnostic agents > Radiocontrast media

Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule

Indications

X-ray contrast media, iodinated

Ipecacuanha

Section

Antidotes and other substances used in poisonings > Non-specific
Oral > Liquid: 0.14% ipecacuanha alkaloids calculated as emetine

Indications

Unspecified injury, poisoning or certain other consequences of external causes

Ipilimumab

Section

Immunomodulators

Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion

Indications

Other specified malignant neoplasms of bronchus or lung

Renal cell carcinoma of kidney, except renal pelvis

Squamous cell carcinoma of oesophagus

Melanoma of skin

Ipratropium bromide

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease
Respiratory > Inhalation > solution: 20 µg per actuation in pressurized metered dose inhaler

Indications

Chronic obstructive pulmonary disease

Asthma

Irinotecan

Section

Cytotoxic medicines

Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial

Indications

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

Isoflurane

Section

General anaesthetics and oxygen > Inhalational medicines
Respiratory > Inhalation > liquid:

Indications

Anaesthetics and therapeutic gases

Isoniazid

Section

Antituberculosis medicines
Parenteral > General injections > IV: 100 mg per mL
Oral > Solid > dispersible tablet: 100 mg (scored)
Oral > Solid > tablet: 100 mg; 300 mg

Indications

Other specified tuberculosis

Tuberculosis

Isoniazid + pyrazinamide + rifampicin

Section

Antituberculosis medicines
Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg

Indications

Tuberculosis

Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim

Section

Medicines for prevention of HIV-related opportunistic infections
Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)

Indications

Other specified prophylactic measures

Isoniazid + rifampicin

Section

Antituberculosis medicines
Oral > Solid > dispersible tablet: 50 mg + 75 mg
Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg

Indications

Tuberculosis

Isoniazid + rifapentine

Section

Antituberculosis medicines
Oral > Solid: 300 mg + 300 mg tablet (scored)

Indications

Latent tuberculosis

Isoprenaline

Section

Antiarrhythmic medicines

Parenteral > General injections > IV: 20 µg per mL in ampoule (hydrochloride)

Oral > Solid: 10 mg (hydrochloride or sulfate); 15 mg (hydrochloride or sulfate)

Indications

Bradycardia

Cardiogenic shock

Isosorbide dinitrate

Section

Antianginal medicines

Oral > Solid: 5 mg sublingual tablet

Indications

Angina pectoris

Itraconazole

Section

Antifungal medicines

Oral > Liquid: 10 mg per mL

Oral > Solid: 100 mg

Indications

Chronic pulmonary aspergillosis

Chromoblastomycosis

Histoplasmosis

Talaromycosis

Sporotrichosis

Paracoccidioidomycosis

Ivacaftor

Section

Medicines for cystic fibrosis

Oral > Solid > tablet: 75 mg; 150 mg

Oral > Solid > granules: 59.5 mg; 75 mg

Indications

Cystic fibrosis

Ivermectin

Section	Indications
Intestinal anthelmintics Oral > Solid > tablet: 3 mg	Strongyloidiasis Ascariasis Trichuriasis Hookworm diseases Ancylostomiasis
Medicines for ectoparasitic infections Oral > Solid > tablet: 3 mg	Scabies
Antifilarials Oral > Solid > tablet: 3 mg	Lymphatic filariasis Onchocerciasis

Kanamycin

Section	Indications
Ophthalmological preparations > Anti-infective agents	Therapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitis

Kanamycin (injection)

Section	Indications
Antituberculosis medicines Parenteral > General injections > IV: 1000 mg powder for injection (vial)	Multi-drug resistant Mycobacterium tuberculosis

Ketamine

Section	Indications
General anaesthetics and oxygen > Injectable medicines Parenteral > General injections > unspecified: 10 mg per mL in vial (as hydrochloride); 50 mg per mL in vial (as hydrochloride)	Anaesthetics and therapeutic gases

Ketoconazole

Section	Indications
Medicines for endocrine disorders Oral > Solid > tablet: 200 mg	Cushing syndrome

Lactulose

Section	Indications
Medicines for other common symptoms in palliative care Oral > Liquid: 3.3 to 3.4 g per 5 mL oral liquid	Palliative care

Lamivudine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Liquid: 50 mg per 5 mL Oral > Solid: 150 mg tablet	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Lamivudine + nevirapine + zidovudine

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Lamivudine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals	Therapeutic equivalent to emtricitabine + tenofovir for Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Therapeutic equivalent to emtricitabine + tenofovir for Contact with or exposure to human immunodeficiency virus

Lamivudine + zidovudine

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Lamotrigine

Section

Antiseizure medicines

Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)

Indications

Epilepsy or seizures

Latanoprost

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops

Indications

Primary open-angle glaucoma

Ledipasvir + sofosbuvir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 90 mg + 400 mg tablet

Indications

Chronic hepatitis C

Lenalidomide

Section

Immunomodulators

Oral > Solid: 25 mg

Indications

Plasma cell myeloma

Lenvatinib

Section

Targeted therapies

Oral > Solid > capsule: 4 mg; 10 mg

Indications

Renal cell carcinoma of kidney, except renal pelvis

Letrozole

Section

Ovulation inducers

Oral > Solid > dosage form: 2.5 mg

Indications

Female infertility without specification whether primary or secondary

Leuporelin

Section

Hormones and antihormones

Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe

Indications

Malignant neoplasms of breast

Malignant neoplasms of prostate

Levamisole

Section

Intestinal anthelmintics

Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)

Indications

Ascariasis

Levetiracetam

Section

Antiseizure medicines

Oral > Liquid: 100 mg per mL

Oral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg

Parenteral > General injections > IV: 100 mg per mL in 5 mL ampoule or vial; 5 mg per mL in 100 mL bag; 10 mg per mL in 100 mL bag; 15 mg per mL in 100 mL bag

Indications

Epilepsy or seizures

Status epilepticus

Levodopa

Section

Medicines for parkinsonism

Oral > Solid: 250 mg

Indications

Parkinson disease

Levodopa + benserazide

Section

Medicines for parkinsonism

Indications

Therapeutic equivalent to levodopa + carbidopa for

Parkinson disease

Levodopa + carbidopa

Section

Medicines for parkinsonism

Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet

Indications

Parkinson disease

Levofloxacin

Section	Indications
Antituberculosis medicines Oral > Solid > dispersible tablet: 100 mg Oral > Solid > tablet: 250 mg; 500 mg; 750 mg	Multi-drug resistant Mycobacterium tuberculosis

Levonorgestrel

Section	Indications
Oral hormonal contraceptives Oral > Solid: 750 µg [2]; 1.5 mg [1] Oral > Solid: 30 µg	Contact with health services for postcoital contraception Contact with health services for contraceptive management
Intrauterine devices Intrauterine system with reservoir containing 52 mg of levonorgestrel.	Contact with health services for insertion of contraceptive device

Levonorgestrel-releasing implant

Section	Indications
Implantable contraceptives Implant > Subdermal: 75 mg per rod (two-rods)	Contact with health services for insertion of contraceptive device

Levothyroxine

Section	Indications
Thyroid hormones and antithyroid medicines Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)	Hypothyroidism

Lidocaine

Section	Indications
Antiarrhythmic medicines Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride)	Ventricular tachyarrhythmia
Local anaesthetics Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution Parenteral > Locoregional injections > Other: 1% (hydrochloride); 2% (hydrochloride); 0.5% (hydrochloride) Local > Topical > unspecified: 2 to 4% (hydrochloride)	Local anaesthetics

Lidocaine + epinephrine

Section

Local anaesthetics

Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine

Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine

Indications

Local anaesthetics

Lindane

Section

Dermatological medicines > Scabicides and pediculicides

Local > Topical > Cream: 1%

Local > Topical > Lotion: 1%

Indications

Scabies

Linezolid

Section

Reserve group antibiotics

Parenteral > General injections > IV: 2 mg per mL in 300 mL bag

Oral > Liquid: 100 mg per 5 mL powder for oral liquid

Oral > Solid: 400 mg tablet; 600 mg tablet

Oral > Solid > dispersible tablet: 150 mg

Oral > Solid > tablet: 600 mg

Antituberculosis medicines

Oral > Solid > dispersible tablet: 150 mg (scored)

Oral > Solid > tablet: 600 mg

Indications

Other specified bacterial diseases

Methicillin resistant *Staphylococcus aureus*

Vancomycin resistant *Staphylococcus aureus*

Vancomycin resistant *Enterococcus*

Multi-drug resistant *Mycobacterium tuberculosis*

Liraglutide

Section

Medicines for endocrine disorders

Parenteral > General injections > SC: 6 mg per mL in 3 mL pre-filled pen

Hypoglycaemic agents

Indications

Obesity

Therapeutic equivalent to *semaglutide* for

Obesity

Therapeutic equivalent to *semaglutide* for

Type 2 diabetes mellitus

Lisinopril + amlodipine

Section	Indications
Antihypertensive medicines Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg	Essential hypertension

Lisinopril + hydrochlorothiazide

Section	Indications
Antihypertensive medicines Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg	Essential hypertension

Lisocabtagene maraleucel

Section	Indications
Antineoplastics and supportive medicines	Therapeutic equivalent to axicabtagene ciloleucel for Diffuse large B-cell lymphomas

Lithium carbonate

Section	Indications
Medicines for bipolar disorders Oral > Solid: 300 mg	Bipolar or related disorders

Loperamide

Section	Indications
Medicines for other common symptoms in palliative care Oral > Solid > dosage form: 2 mg	Palliative care

Lopinavir + ritonavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable) Oral > Solid > dosage form: 40 mg + 10 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Loratadine

Section	Indications
Antiallergics and medicines used in anaphylaxis Oral > Liquid: 1 mg per mL Oral > Solid > tablet: 10 mg; 5 mg (chewable); 10 mg (chewable)	Allergic or hypersensitivity conditions of unspecified type

Lorazepam

Section	Indications
Medicines for anxiety disorders	Therapeutic equivalent to diazepam for Anxiety
Antiseizure medicines Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule	Status epilepticus

Losartan

Section	Indications
Antihypertensive medicines Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet	Essential hypertension
Medicines used in heart failure Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet	Heart failure

Lovastatin

Section	Indications
Lipid-lowering agents	Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia
	Therapeutic equivalent to simvastatin for Coronary atherosclerosis

Magnesium sulfate

Section	Indications
Antiseizure medicines Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume) Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)	Severe pre-eclampsia Eclampsia

Malaria vaccine

Section	Indications
Immunologicals > Vaccines All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against certain specified single infectious diseases

Mannitol

Section	Indications
Diuretics Parenteral > General injections > IV: 10% solution; 20% solution	Ocular hypertension Cerebral oedema

Measles vaccine

Section	Indications
Immunologicals > Vaccines All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against measles alone

Mebendazole

Section	Indications
Intestinal anthelmintics Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)	Ascariasis Enterobiasis Trichuriasis Hookworm diseases
Cysticidal medicines Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)	Other specified echinococcosis

Medroxyprogesterone acetate

Section	Indications
Injectable hormonal contraceptives Parenteral > General injections > IM: 150 mg per mL in 1 mL vial Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system	Contact with health services for reasons associated with reproduction
Progestogens Oral > Solid: 5 mg	Excessive menstruation with irregular cycle

Mefloquine

Section	Indications
Antimalarial medicines > Medicines for curative treatment Oral > Solid: 250 mg tablet (hydrochloride)	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
Antimalarial medicines > Medicines for chemoprophylaxis in travellers Oral > Solid > tablet: 250 mg (scored) (as hydrochloride)	Malaria due to Plasmodium falciparum
Antimalarial medicines > Medicines for chemoprevention Oral > Solid: 250 mg tablet (hydrochloride)	Malaria due to Plasmodium falciparum

Meglumine antimoniate

Section	Indications
Antileishmaniasis medicines Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule	Visceral leishmaniasis Cutaneous leishmaniasis Mucocutaneous leishmaniasis

Meglumine iotroxate

Section	Indications
Diagnostic agents > Radiocontrast media Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL	X-ray contrast media, iodinated

Melarsoprol

Section	Indications
Medicines for the treatment of 2nd stage African trypanosomiasis Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)	Rhodesiense trypanosomiasis Gambiense trypanosomiasis

Melphalan

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg in vial powder for injection Oral > Solid: 2 mg	Plasma cell myeloma

Meningococcal meningitis vaccine

Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against single bacterial diseases

Mercaptopurine

Section

Cytotoxic medicines

Oral > Solid: 50 mg tablet

Oral > Liquid: 20 mg per mL

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Langerhans cell histiocytosis

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Meropenem

Section

Watch group antibiotics

Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Medicines for bacterial central nervous system infections

Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Antituberculosis medicines

Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

Second choice

Neutropenia (high-risk)

Peritoneal abscess (severe)

Peritonitis (severe)

Neonatal meningitis

Second choice

Neonatal meningitis

Multi-drug resistant *Mycobacterium tuberculosis*

Meropenem + vaborbactam

Section

Reserve group antibiotics

Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Carbapenem resistant *Acinetobacter baumannii*

Mesalazine

Section

Anti-inflammatory medicines

Indications

Therapeutic equivalent to **sulfasalazine** for

Crohn disease site

Therapeutic equivalent to **sulfasalazine** for

Ulcerative colitis

Mesna

Section

Supportive medicines

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule

Oral > Solid: 400 mg; 600 mg

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule

Oral > Solid > tablet: 400 mg; 600 mg

Oral > Other: 600 mg

Oral > Solid > tablet: 400 mg

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified malignant neoplasms of the ovary

Osteosarcoma of bone and articular cartilage of other specified sites

Burkitt lymphoma including Burkitt leukaemia

Ewing sarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

Germ cell tumour of testis

Metformin

Section

Oral hypoglycaemic agents

Oral > Solid: 500 mg (hydrochloride)

Indications

Type 2 diabetes mellitus

Methadone

Section

Medicines for opioid use disorders

Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)

Opioid analgesics

Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 25 mg per 5 mL (methadone hydrochloride); 50 mg per 5 mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)

Oral > Solid > tablet: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride)

Indications

Opioid dependence

Chronic cancer pain

Methimazole

Section

Thyroid hormones and antithyroid medicines

Oral > Solid > tablet: 5 mg; 10 mg

Indications

Thyrotoxicosis

Methionine

Section

Antidotes and other substances used in poisonings > Specific

Oral > Solid: 250 mg (DL)

Indications

Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs

Methotrexate

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg in vial (as sodium salt) Oral > Solid: 2.5 mg (as sodium salt) Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection	Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant trophoblastic neoplasms of placenta Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Burkitt lymphoma including Burkitt leukaemia
Dermatological medicines > Medicines affecting skin differentiation and proliferation Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)	Psoriasis of unspecified type
Disease-modifying anti-rheumatic drugs (DMARDs) Oral > Solid > tablet: 2.5 mg (as sodium salt)	Rheumatoid arthritis, serology unspecified
Immunomodulators for non-malignant disease Parenteral > General injections > SC: pre-filled syringe in multiple strengths	Crohn disease site Psoriatic arthritis
Medicines for juvenile joint diseases Oral > Solid > tablet: 2.5 mg (as sodium salt)	Juvenile idiopathic arthritis

Methoxy polyethylene glycol-epoetin beta

Section	Indications
Antianaemia medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease

Methyldopa

Section	Indications
Antihypertensive medicines Oral > Solid: 250 mg	Essential hypertension Gestational hypertension

Methylergometrine

Section

Uterotonics

Indications

Therapeutic equivalent to [ergometrine](#) for

Postpartum haemorrhage

Methylphenidate

Section

Medicines for mental and behavioural disorders

Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 20 mg (hydrochloride); 18 mg extended-release (hydrochloride); 27 mg extended-release (hydrochloride); 36 mg extended-release (hydrochloride); 54 mg extended-release (hydrochloride); 72 mg extended-release (hydrochloride)

Oral > Solid > capsule: 10 to 60 mg extended-release (hydrochloride)

Indications

Attention deficit hyperactivity disorder

Methylprednisolone

Section

Hormones and antihormones

Parenteral > General injections > IV: 40 mg in vial (as sodium succinate); 125 mg in vial (as sodium succinate)

Parenteral > General injections > IV: 40 mg in vial (as sodium succinate) powder for injection; 125 mg in vial (as sodium succinate) powder for injection

Indications

Burkitt lymphoma including Burkitt leukaemia

Lymphoid leukaemia, not elsewhere classified

Methylthioninium chloride

Section

Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule

Indications

Acquired methaemoglobinaemia

Metoclopramide

Section	Indications
Medicines for other common symptoms in palliative care Oral > Liquid: 5 mg per 5 mL Oral > Solid: 10 mg (hydrochloride) Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)	Palliative care
Antiemetic medicines Oral > Liquid: 5 mg per 5 mL Oral > Solid: 10 mg (scored) (hydrochloride) Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)	Nausea or vomiting

Metoprolol

Section	Indications
Antianginal medicines	Therapeutic equivalent to bisoprolol for Angina pectoris
Medicines used in heart failure	Therapeutic equivalent to bisoprolol for Heart failure
Antihypertensive medicines	Therapeutic equivalent to bisoprolol for Essential hypertension
Antiarrhythmic medicines	Therapeutic equivalent to bisoprolol for Cardiac arrhythmia

Metronidazole

Section

Access group antibiotics

Oral > Liquid: 200 mg per 5 mL (as benzoate)

Oral > Solid: 200 to 500 mg tablet

Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
Injection

Local > Rectal > Suppository: 500 mg; 1 g

Parenteral > General injections > unspecified: 500 mg per 100 mL in vial

Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg

Antiamoebic and anti giardiasis medicines

Oral > Liquid: 200 mg per 5 mL (as benzoate)

Parenteral > General injections > unspecified: 500 mg in 100 mL vial

Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg

Indications

First choice

Intestinal infections due to *Clostridioides difficile*

Trichomoniasis

co-prescribed with cefazolin

Other specified prophylactic measures

co-prescribed with cefotaxime

Peritonitis (severe)

co-prescribed with cefotaxime

Peritonitis (mild-moderate)

co-prescribed with cefotaxime

Peritoneal abscess (mild-moderate)

co-prescribed with cefotaxime

Peritoneal abscess (severe)

co-prescribed with ceftriaxone

Necrotising fasciitis

co-prescribed with ceftriaxone

Peritonitis (severe)

co-prescribed with ceftriaxone

Peritoneal abscess (mild-moderate)

co-prescribed with ceftriaxone

Peritoneal abscess (severe)

co-prescribed with ceftriaxone

Peritonitis (mild-moderate)

Second choice

co-prescribed with ciprofloxacin

Peritonitis (mild-moderate)

co-prescribed with ciprofloxacin

Peritoneal abscess (mild-moderate)

Other indications

Bacterial infection of unspecified site

Amoebiasis

Micafungin

Section

[Antifungal medicines](#)

Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection

Indications

Systemic or invasive candidosis

Miconazole

Section

[Dermatological medicines](#) > [Antifungal medicines](#)

Local > Topical > Cream: 2% (nitrate)

Local > Topical > Ointment: 2% (nitrate)

Indications

Fungal infection of the skin

Midazolam

Section

Antiseizure medicines

Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial (for buccal administration); 5 mg per mL in 1 mL vial (for buccal administration); 5 mg per mL in 3 mL vial (for buccal administration)

Local > Buccal > Solution: 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)

Preoperative medication and sedation for short-term procedures

Parenteral > General injections > IV: 1 mg per mL in 5 mL vial; 5 mg per mL in 1 mL vial; 5 mg per mL in 3 mL vial

Oral > Liquid: 2 mg per mL

Oral > Solid > dosage form: 15 mg; 7.5 mg

Medicines for other common symptoms in palliative care

Oral > Liquid: 2 mg per mL

Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial; 5 mg per mL in 1 mL vial; 5 mg per mL in 3 mL vial

Local > Buccal > Solution: ; 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)

Oral > Solid > dosage form: 7.5 mg; 15 mg

Indications

Status epilepticus

Therapeutic equivalent to lorazepam for

Status epilepticus

Sedative-hypnotic and anxiolytic drugs

Palliative care

Mifepristone - misoprostol

Section

Medicines for medical abortion

Oral > Solid > tablet: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package

Indications

Unspecified time of fetal death, cause not specified

Induced abortion

Miltefosine

Section

Antileishmaniasis medicines

Oral > Solid: 10 mg; 50 mg

Indications

Visceral leishmaniasis

Mucocutaneous leishmaniasis

Cutaneous leishmaniasis

Misoprostol

Section

Uterotonics

Local > Vaginal > tablet: 25 µg

Oral > Solid: 200 µg

Medicines for medical abortion

Oral > Solid > tablet: 200 µg

Indications

Unspecified obstetric condition

Postpartum haemorrhage

Spontaneous abortion, incomplete, without complication

Mometasone

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to **budesonide** for

Asthma

Mometasone + formoterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to **budesonide + formoterol** for

Asthma

Morphine

Section

Preoperative medication and sedation for short-term procedures

Parenteral > General injections > IV: 1 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 2 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 10 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate)

Opioid analgesics

Oral > Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate); 5 mg per 5 mL (morphine hydrochloride or morphine sulfate)

Parenteral > General injections > unspecified: 1 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 2 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 10 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate)

Oral > Solid > tablet: 10 mg immediate release (morphine sulfate)

Oral > Solid > dosage form: 5 mg slow-release (morphine hydrochloride or morphine sulfate); 10 mg slow-release (morphine hydrochloride or morphine sulfate); 30 mg slow-release (morphine hydrochloride or morphine sulfate); 60 mg slow-release (morphine hydrochloride or morphine sulfate); 100 mg slow-release (morphine hydrochloride or morphine sulfate); 200 mg slow-release (morphine hydrochloride or morphine sulfate)

Oral > Solid > granules: 20 mg (morphine sulfate); 30 mg (morphine sulfate); 60 mg (morphine sulfate); 100 mg (morphine sulfate); 200 mg (morphine sulfate)

Indications

Opioids or related analgesics and agents affecting opioid receptors

Pain

Moxidectin

Section

Antifilarials

Oral > Solid > tablet: 2 mg

Indications

Therapeutic equivalent to ivermectin for

Lymphatic filariasis

Therapeutic equivalent to ivermectin for

Onchocerciasis

Moxifloxacin

Section

Antituberculosis medicines

Oral > Solid > tablet: 400 mg

Oral > Solid > dispersible tablet: 100 mg

Indications

Tuberculosis

Multi-drug resistant Mycobacterium tuberculosis

Mpox vaccine

Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Multiple micronutrient powder

Section

Vitamins and minerals

Sachets containing:

- iron (elemental) 12.5 mg (as coated ferrous fumarate)
- zinc (elemental) 5 mg
- vitamin A 300 micrograms
- with or without other micronutrients at recommended daily values

Indications

Iron deficiency anaemia

Multiple micronutrient supplement

Section

Other medicines administered to the mother

Tablet containing:

Vit A: 800 mcg retinol activity equivalent

Vit C: 70 mg

Vit D: 5 mcg (200 IU)

Vit E: 10 mg alpha tocopherol equivalent

Vit B1: 1.4 mg

Vit B2: 1.4 mg

Vit B3: 18 mg niacin equivalent

Vit B6: 1.9 mg

Folic acid: 400 mcg

Vit B12: 2.6 mcg

Iron: 30 mg

Iodine: 150 mcg

Zinc: 15 mg

Selenium: 65 mcg

Copper: 2 mg

Indications

Maternal care for other specified conditions predominantly related to pregnancy

Mumps vaccine

Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against mumps alone

Mupirocin

Section

Dermatological medicines > Anti-infective medicines

Local > Topical > Cream: 2% (as mupirocin calcium)

Local > Topical > Ointment: 2%

Indications

Superficial bacterial folliculitis

Impetigo

Nadroparin

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to enoxaparin for

Acute ischaemic heart disease

Therapeutic equivalent to enoxaparin for

Venous thromboembolism

Nalidixic acid

Section

Anti-infective medicines

Oral > Solid: 250 mg; 500 mg

Indications

Shigella resistant to unspecified antibiotic

Naloxone

Section

Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)

Indications

Unintentional exposure to or harmful effects of opioids or related analgesics

Naltrexone

Section

Medicines for alcohol use disorders

Parenteral > General injections > IM: 380 mg in vial (extended-release)

Oral > Solid > tablet: 50 mg

Indications

Disorders due to use of alcohol

Naproxen

Section

Medicines for acute migraine attacks

Indications

Therapeutic equivalent to [ibuprofen](#) for

Migraine

Natamycin

Section

Ophthalmological preparations > Anti-infective agents
Local > Ophthalmological > Suspension: 5% eye drops

Indications

Infectious keratitis

Nelfinavir

Section

Antiretrovirals > Protease inhibitors
Oral > Solid: 250 mg (as mesilate)
Oral > Other: 50 mg per g oral powder

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Neostigmine

Section

Medicines for myasthenia gravis
Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
Oral > Solid > tablet: 15 mg (neostigmine bromide)

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
Oral > Solid > tablet: 15 mg (neostigmine bromide)

Indications

Myasthenia gravis

Myasthenia gravis

Anticholinesterase reversible

Netilmicin

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to [gentamicin](#) for

Other specified conjunctivitis

Therapeutic equivalent to [gentamicin](#) for

Infectious blepharitis

Nevirapine

Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

Oral > Liquid: 50 mg per 5 mL

Oral > Solid > dispersible tablet: 50 mg

Oral > Solid > tablet: 200 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Niclosamide

Section

Intestinal anthelmintics

Oral > Solid: 500 mg tablet (chewable)

Indications

Hymenolepiasis

Diphyllobothriasis

Taeniasis due to *Taenia saginata*

Taeniasis due to *Taenia solium*

Nicotinamide

Section

Vitamins and minerals

Oral > Solid: 50 mg

Indications

Pellagra

Nicotine replacement therapy

Section

Medicines for nicotine use disorders

Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour

Oral > Solid > lozenge: 2 mg; 4 mg lozenge

Local > Buccal > Oral spray: 1 mg per actuation

Local > Buccal > Chewing gum: 2 mg; 4 mg

Indications

Nicotine dependence

Nifedipine

Section

Antioxytocs (tocolytics)

Oral > Solid: 10 mg (immediate-release)

Antianginal medicines

Oral > Solid: 10 mg

Antihypertensive medicines

Oral > Solid: 10 mg tablet; sustained-release formulations

Indications

Preterm labour without delivery

Angina pectoris

Essential hypertension

Nifurtimox

Section	Indications
American trypanosomiasis Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)	Chagas disease
Medicines for the treatment of 2nd stage African trypanosomiasis Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)	Gambiense trypanosomiasis

Nilotinib

Section	Indications
Targeted therapies Oral > Solid > capsule: 150 mg; 200 mg	Chronic myeloid leukaemia, not elsewhere classified

Nilutamide

Section	Indications
Hormones and antihormones	Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate

Nitrofurantoin

Section	Indications
Access group antibiotics Oral > Liquid: 25 mg per 5 mL oral liquid Oral > Solid > dosage form: 100 mg; 50 mg	First choice Infectious cystitis

Nitrous oxide

Section	Indications
General anaesthetics and oxygen > Inhalational medicines Respiratory > Inhalation:	Anaesthetics and therapeutic gases

Nivolumab

Section

Immunomodulators

Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion

Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion

Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion

Indications

Therapeutic equivalent to pembrolizumab for

Melanoma of skin

Other specified malignant neoplasms of bronchus or lung

Melanoma of skin

Renal cell carcinoma of kidney, except renal pelvis

Squamous cell carcinoma of oesophagus

Adenocarcinoma of oesophagogastric junction

Adenocarcinoma of stomach

Norethisterone

Section

Oral hormonal contraceptives

Oral > Solid: 350 µg

Progestogens

Oral > Solid: 5 mg

Indications

Contact with health services for contraceptive management

Excessive menstruation with irregular cycle

Therapeutic equivalent to medroxyprogesterone acetate for

Excessive menstruation with irregular cycle

Norethisterone enantate

Section

Injectable hormonal contraceptives

Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution

Indications

Contact with health services for reasons associated with reproduction

Normal immunoglobulin

Section	Indications
Human immunoglobulins Parenteral > General injections > IV: 5% protein solution; 10% protein solution Parenteral > General injections > IM: 16% protein solution Parenteral > General injections > SC: 15% protein solution; 16% protein solution Medicines for Guillain-Barré syndrome Parenteral > General injections > IV: 5% protein solution; 10% protein solution	Primary immunodeficiencies Langerhans cell histiocytosis Mucocutaneous lymph node syndrome Acute inflammatory demyelinating polyneuropathy

Nystatin

Section	Indications
Antifungal medicines Oral > Liquid: 100000 IU per mL Local > Topical > Other: 100000 IU pessary Oral > Solid > dosage form: 500000 IU Oral > Solid > lozenge: 100000 IU	Candidosis

Ocrelizumab

Section	Indications
Medicines for multiple sclerosis Parenteral > General injections > IV: 30 mg per mL in 10 mL vial Parenteral > General injections > IV: 30 mg per mL in 10 vial concentrate for solution	Relapsing-remitting multiple sclerosis Multiple sclerosis

Octreotide

Section	Indications
Medicines for disorders of the pituitary hormone system Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)	Acromegaly or pituitary gigantism

Ofloxacin

Section	Indications
Antituberculosis medicines Oral > Solid: 200 mg; 400 mg	Multi-drug resistant Mycobacterium tuberculosis
Ear, nose and throat medicines [c]	Therapeutic equivalent to ciprofloxacin for Infectious diseases of external ear
Ophthalmological preparations > Anti-infective agents Local > Ophthalmological > Solution (eye drops): 0.3%	Other specified conjunctivitis Infectious keratitis

Olanzapine

Section	Indications
Medicines for psychotic disorders Parenteral > General injections > IM: 10 mg in vial powder for injection	Therapeutic equivalent to risperidone for Schizophrenia or other primary psychotic disorders Schizophrenia or other primary psychotic disorders

Omadacycline

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 100 mg lyophilized powder for injection Oral > Solid: 300 mg	Methicillin resistant Staphylococcus aureus

Ombitasvir + paritaprevir + ritonavir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet	Chronic hepatitis C

Omeprazole

Section

Antiulcer medicines

Parenteral > General injections > IV: 40 mg in vial

Oral > Liquid: 1 mg per mL powder for oral liquid; 4 mg per mL powder for oral liquid

Oral > Solid > dosage form: 10 mg; 20 mg; 40 mg

Indications

Gastrointestinal bleeding

Peptic ulcer, site unspecified

Gastro-oesophageal reflux disease

Ondansetron

Section

Medicines for other common symptoms in palliative care

Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (as hydrochloride dihydrate); 2 mg per mL in 4 mL ampoule (as hydrochloride dihydrate)

Oral > Liquid: 4 mg per 5 mL (as hydrochloride dihydrate)

Oral > Solid: 4 mg (as hydrochloride dihydrate); 8 mg (as hydrochloride dihydrate)

Antiemetic medicines

Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (as hydrochloride dihydrate); 2 mg per mL in 4 mL ampoule

Oral > Liquid: 4 mg per 5 mL (as hydrochloride dihydrate)

Oral > Solid > dosage form: 4 mg (as hydrochloride dihydrate); 8 mg (as hydrochloride dihydrate); 24 mg (as hydrochloride dihydrate)

Indications

Palliative care

Nausea or vomiting

Oral rehydration salts

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Oral Powder for dilution in 200 mL, 500 mL, 1 L: - glucose 75 mEq or mmol/L - sodium 75 mEq or mmol/L - chloride 65 mEq or mmol/L - potassium 20 mEq or mmol/L - citrate 10 mEq or mmol/L - osmolarity 245 mOsm/L - glucose 13.5 g/L - sodium chloride 2.6 g/L - potassium chloride 1.5 g/L - trisodium citrate dihydrate 2.9 g/L Oral rehydration Powder for dilution in 200 mL, 500 mL, 1 L: - glucose 75 mEq or mmol/L - sodium 75 mEq or mmol/L - chloride 65 mEq or mmol/L - potassium 20 mEq or mmol/L - citrate 10 mEq or mmol/L - osmolarity 245 mOsm/L - glucose 13.5 g/L - sodium chloride 2.6 g/L - potassium chloride 1.5 g/L - trisodium citrate dihydrate 2.9 g/L	Other specified disorders of fluid, electrolyte or acid-base balance Diarrhoea

Oral rehydration salts - zinc sulfate

Section	Indications
Medicines used in diarrhoea Oral > Other: ORS powder for dilution and zinc sulfate dispersible tablet 20 mg (co-packaged)	Diarrhoea

Oseltamivir

Section

Other antivirals

Oral > Liquid: 6 mg per mL (as phosphate) powder for oral liquid

Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)

Indications

Influenza due to identified seasonal influenza virus

Osimertinib

Section

Targeted therapies

Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)

Indications

Other specified malignant neoplasms of bronchus or lung

Oxaliplatin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial

Indications

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of colon

Oxamniquine

Section

Antischistosomes and other antitrematode medicines

Oral > Liquid: 250 mg per 5 mL

Oral > Solid > capsule: 250 mg

Indications

Schistosomiasis due to *Schistosoma mansoni*

Oxazolindinones

Section

Reserve group antibiotics

.

Indications

Other specified bacterial diseases

Oxycodone

Section

Opioid analgesics

Indications

Therapeutic equivalent to morphine for

Pain

Oxygen

Section

General anaesthetics and oxygen > Inhalational medicines
Respiratory > Inhalation: (medical gas)

Medical gases

Respiratory > Inhalation:

Indications

Anaesthetics and therapeutic gases

Respiratory failure as acute or chronic

Oxytetracycline

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to tetracycline for

Other specified conjunctivitis

Therapeutic equivalent to tetracycline for

Infectious keratitis

Therapeutic equivalent to tetracycline for

Infectious blepharitis

Therapeutic equivalent to tetracycline for

Trachoma

Oxytocin

Section

Uterotonics

Parenteral > General injections > unspecified: 10 IU per mL

Indications

Postpartum haemorrhage

P-aminosalicylate sodium

Section

Antituberculosis medicines

Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid)
powder for oral solution

Indications

Multi-drug resistant Mycobacterium tuberculosis

P-aminosalicylic acid

Section

Antituberculosis medicines

Oral > Solid: 4 g granules in sachet

Indications

Multi-drug resistant Mycobacterium tuberculosis

Paclitaxel

Section

Cytotoxic medicines

Parenteral > General injections > IV: 6 mg per mL

Indications

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of nasopharynx

Kaposi sarcoma of unspecified primary site

Other specified malignant neoplasms of breast

Other specified carcinomas of ovary

Malignant neoplasms of breast

Malignant neoplasms of cervix uteri

Palbociclib

Section

Targeted therapies

Oral > Solid: 75 mg; 100 mg; 125 mg

Indications

Other specified malignant neoplasms of breast

Paliperidone

Section

Medicines for psychotic disorders

Parenteral > General injections > IM: 25 mg in pre-filled syringe (as palmitate); 50 mg in pre-filled syringe (as palmitate); 75 mg in pre-filled syringe (as palmitate); 100 mg in pre-filled syringe (as palmitate); 150 mg in pre-filled syringe (as palmitate)

Indications

Therapeutic equivalent to risperidone for

Schizophrenia or other primary psychotic disorders

Schizophrenia or other primary psychotic disorders

Palonosetron

Section

Medicines for other common symptoms in palliative care

Antiemetic medicines

Indications

Therapeutic equivalent to ondansetron for

Palliative care

Therapeutic equivalent to ondansetron for

Nausea or vomiting

Pancreatic enzymes

Section	Indications
Gastrointestinal medicines Capsule (modified release): 10 000 lipase units + 8000 amylase units + 600 protease units; 25 000 lipase units + 18 000 amylase units + 1000 protease units. *Units expressed in Ph. Eur	Enzyme intestinal
Medicines for cystic fibrosis Capsule (modified release): 10 000 lipase units + 8000 amylase units + 600 protease units; 25 000 lipase units + 18 000 amylase units + 1000 protease units. *Units expressed in Ph. Eur	Cystic fibrosis

Panitumumab

Section	Indications
Targeted therapies Parenteral > General injections > IV: 20 mg per mL in 5 mL vial concentrate for solution for infusion; 20 mg per mL in 20 mL vial	Other specified malignant neoplasms of large intestine

Paracetamol (acetaminophen)

Section	Indications
Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs) Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL Local > Rectal > Suppository: 100 mg; 250 mg Oral > Solid > dispersible tablet: 100 mg; 250 mg Oral > Solid > tablet: 250 mg; 325 mg; 500 mg	Pain
Medicines for acute migraine attacks Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL Local > Rectal > Suppository: 250 mg Oral > Solid > dispersible tablet: 100 mg; 250 mg Oral > Solid > tablet: 250 mg; 325 mg; 500 mg	Migraine

Paromomycin

Section

Antileishmaniasis medicines

Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)

Antiamoebic and anti giardiasis medicines

Oral > Liquid: 125 mg per 5 mL as sulfate

Oral > Solid: 250 mg as sulfate

Indications

Visceral leishmaniasis

Amoebiasis

Pegaspargase

Section

Cytotoxic medicines

Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection

Indications

Lymphoid leukaemia, not elsewhere classified

Pegfilgrastim

Section

Immunomodulators

Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe

Indications

Acquired neutropaenia

Pegylated interferon alfa (2a)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe

Indications

Chronic hepatitis C

Pegylated interferon alfa (2b)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe

Indications

Chronic hepatitis C

Pembrolizumab

Section

Immunomodulators

Parenteral > General injections > IV: 25 mg per mL in 4 mL vial

Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection

Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion

Indications

Melanoma of skin

Malignant neoplasms of cervix uteri

Other specified malignant neoplasms of large intestine

Other specified malignant neoplasms of bronchus or lung

Adenocarcinoma of stomach

Squamous cell carcinoma of hypopharynx and variants

Renal cell carcinoma of kidney, except renal pelvis

Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx

Squamous cell carcinoma of oropharynx

Carcinoma of breast, specialised type

Squamous cell carcinoma of nasopharynx

Squamous cell carcinoma of oesophagus

Malignant neoplasms of oesophagogastric junction

Therapeutic equivalent to nivolumab for

Melanoma of skin

Penicillamine

Section

Antidotes and other substances used in poisonings > Specific

Oral > Solid: 250 mg

Disease-modifying anti-rheumatic drugs (DMARDs)

Oral > Solid: 250 mg

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Rheumatoid arthritis, serology unspecified

Pentamidine

Section	Indications
Antileishmaniasis medicines Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate)	Visceral leishmaniasis
Antipneumocystosis and antitoxoplasmosis medicines Oral > Solid > tablet: 200 mg (as isethionate); 300 mg (as isethionate)	Pneumocystosis
Medicines for the treatment of 1st stage African trypanosomiasis Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection	Gambiense trypanosomiasis

Perindopril + amlodipine + indapamide

Section	Indications
Antihypertensive medicines Oral > Solid > dosage form: 5 mg (arginine) + 5 mg + 1.25 mg; 5 mg (arginine) + 10 mg + 1.25 mg; 10 mg (arginine) + 5 mg + 2.5 mg; 10 mg (arginine) + 10 mg + 2.5 mg	Essential hypertension

Permethrin

Section	Indications
Dermatological medicines > Scabicides and pediculicides Local > Topical > Lotion: 1% Local > Topical > Cream: 5%	Pediculosis corporis Pediculosis capitis Scabies

Pertussis vaccine

Section	Indications
Immunologicals > Vaccines All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against pertussis alone

Pertuzumab

Section	Indications
Targeted therapies Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution	Carcinoma of breast, specialised type

Phenelzine

Section

Medicines for depressive disorders

Oral > Solid > dosage form: 15 mg (as sulfate)

Indications

Other specified depressive disorders

Phenobarbital

Section

Antiseizure medicines

Parenteral > General injections > IV: 200 mg per mL (phenobarbital sodium); 30 mg per mL (phenobarbital sodium); 60 mg per mL (phenobarbital sodium)

Oral > Liquid: 15 mg per 5 mL

Oral > Solid > tablet: 15 mg; 30 mg; 60 mg; 100 mg

Indications

Status epilepticus

Epilepsy or seizures

Phenoxymethylpenicillin

Section

Access group antibiotics

Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid

Oral > Solid: 250 mg (as potassium salt) tablet

Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)

Indications

First choice

Acute pharyngitis

Periapical abscess without sinus

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Other indications

Bacterial infection of unspecified site

Phenytoin

Section

Antiseizure medicines

Oral > Liquid: 30 mg per 5 mL (phenytoin)

Parenteral > General injections > unspecified: 50 mg per mL in vial (phenytoin sodium)

Oral > Solid > tablet: 50 mg (phenytoin) (chewable)

Oral > Solid > dosage form: 25 mg (phenytoin sodium); 50 mg (phenytoin sodium); 100 mg (phenytoin sodium)

Indications

Epilepsy or seizures

Phosphorus

Section

Medicines for endocrine disorders

Oral > Other: 500 mg in sachet (elemental phosphorus) granules

Oral > Solid > tablet: 250 mg (elemental phosphorus); 500 mg (elemental phosphorus); 500 mg (elemental phosphorus) (effervescent)

Indications

Hypophosphataemic rickets

Phytomenadione

Section

Medicines affecting coagulation

Parenteral > General injections > IV: 1 mg per 0.5 mL in ampoule; 10 mg per mL in ampoule; 1 mg per mL in ampoule; 2 mg per 0.2 mL in ampoule mixed micelle solution; 10 mg per mL in ampoule mixed micelle solution

Oral > Solid > tablet: 5 mg tablet

Indications

Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors

Haemorrhagic or haematological disorders of fetus or newborn

Pilocarpine

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)

Indications

Acute angle closure with pupillary block

Ocular hypertension

Primary open-angle glaucoma

Piperacillin + tazobactam

Section

Watch group antibiotics

Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

Indications

First choice

Peritoneal abscess (severe)

Other specified pneumonia (Hospital-acquired pneumonia)

Neutropenia (high-risk)

Peritonitis (severe)

co-prescribed with clindamycin

Necrotising fasciitis

Platelets

Section

Blood and blood components

Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis

Plazomicin

Section

Reserve group antibiotics

Parenteral > General injections > IV: 500 mg per 10 mL

Indications

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Pneumococcal vaccine

Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against single bacterial diseases

Podophyllotoxin

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to [podophyllum resin](#) for

Anogenital warts

Therapeutic equivalent to [podophyllum resin](#) for

Plantar warts

Podophyllum resin

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Local > Topical > Solution: 10 to 25%

Indications

Anogenital warts

Plantar warts

Poliomyelitis vaccine

Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against poliomyelitis

Polygeline

Section	Indications
Plasma substitutes Parenteral > General injections > IV: 3.5% injectable solution Parenteral > General injections > IV: 3.5% in solution	Therapeutic equivalent to dextran 70 for Hypovolaemia Hypovolaemia

Polymyxin B (injection)

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)	Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales

Polymyxins

Section	Indications
Reserve group antibiotics .	Other specified bacterial diseases

Porcatant alfa

Section	Indications
Medicines administered to the neonate [c] Respiratory > Suspension: 80 mg per mL for intratracheal instillation	Respiratory distress syndrome of newborn

Potassium chloride

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Oral Oral > Liquid: powder for solution	Hypokalaemia
Solutions correcting water, electrolyte and acid-base disturbances > Parenteral Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol/mL and Cl- 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K+ 1 mmol/mL and Cl- 2 mmol/mL); 15% solution for dilution (equivalent to K+ 2 mmol/mL and Cl- 2 mmol/mL)	Hypokalaemia

Potassium ferric hexacyanoferrate (Prussian blue)

Section

Antidotes and other substances used in poisonings > Specific
Oral > Solid: Powder for oral administration

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Potassium iodide

Section

Antifungal medicines
Local > Topical > Solution: Saturated solution

Thyroid hormones and antithyroid medicines
Oral > Solid > tablet: 65 mg (scored)

Indications

Sporotrichosis

Thyrotoxicosis

Potassium permanganate

Section

Dermatological medicines > Anti-infective medicines
Local > Topical > Solution: aqueous solution: 1:10 000

Indications

Tropical phagedaenic ulcer

Pemphigus

Other specified pyogenic bacterial infection of skin and subcutaneous tissue

Impetigo

Povidone iodine

Section

Antiseptics
Local > Topical > Solution: 10% (equivalent to 1% available iodine)

Indications

Povidone iodine

Pralidoxime

Section

Antidotes and other substances used in poisonings > Specific
.

Indications

Exposure to or harmful effects of undetermined intent of pesticides

Pramipexole

Section

Antiseizure medicines

Oral > Solid: 125 µg immediate-release; 250 mg immediate-release; 500 µg immediate-release; 750 µg immediate-release; 1 mg immediate-release; 1.5 mg immediate-release; 375 µg extended-release; 750 µg extended-release; 1.5 mg extended-release; 2.25 mg extended-release; 3 mg extended-release; 3.75 mg extended-release; 4.5 extended-release

Indications

Parkinson disease

Pravastatin

Section

Lipid-lowering agents

Indications

Therapeutic equivalent to [simvastatin](#) for

Mixed hyperlipidaemia

Therapeutic equivalent to [simvastatin](#) for

Coronary atherosclerosis

Praziquantel

Section

Antischistosomes and other antitrematode medicines

Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Indications

Paragonimiasis

Clonorchiasis

Opisthorchiasis

Schistosomiasis

Intestinal anthelmintics

Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Taeniasis due to *Taenia saginata*

Taeniasis due to *Taenia solium*

Hymenolepiasis

Diphyllobothriasis

Cysticidal medicines

Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Cysticercosis of central nervous system

Precipitated sulfur

Section

[Dermatological medicines](#) > [Scabicides and pediculicides](#)

Local > Topical > Ointment:

Indications

Therapeutic equivalent to [benzyl benzoate](#) for

[Pthiriasis](#)

Therapeutic equivalent to [benzyl benzoate](#) for

[Pediculosis corporis](#)

Therapeutic equivalent to [benzyl benzoate](#) for

[Pediculosis capitis](#)

Therapeutic equivalent to [benzyl benzoate](#) for

[Scabies](#)

Prednisolone

Section

Hormones and antihormones

Oral > Liquid: 5 mg per mL

Oral > Solid: 5 mg; 25 mg

Anti-inflammatory medicines

Local > Rectal > Retention enema:

Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)

Antiallergics and medicines used in anaphylaxis

Oral > Liquid: 5 mg per mL

Oral > Solid: 5 mg; 25 mg

Ophthalmological preparations > Anti-inflammatory agents

Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)

Adrenal hormones and synthetic substitutes

Oral > Solid > tablet: 1 mg

Medicines for cluster headache

Oral > Solid > tablet: 25 mg; 5 mg

Antiseizure medicines

Oral > Liquid: 1 mg per mL

Oral > Solid > tablet: 1 mg; 5 mg; 10 mg

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Plasma cell myeloma

Follicular lymphoma

Malignant neoplasms of prostate

Hodgkin lymphoma

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Diffuse large B-cell lymphoma, not otherwise specified

Therapeutic equivalent to hydrocortisone for

Crohn disease site

Crohn disease site

Ulcerative colitis

Allergic or hypersensitivity conditions of unspecified type

Scleritis

Anterior uveitis

Adrenocortical insufficiency

Trigeminal autonomic cephalalgias

Infantile spasms

Prednisone

Section

Hormones and antihormones

Indications

Therapeutic equivalent to prednisolone for

Plasma cell myeloma

Therapeutic equivalent to prednisolone for

Follicular lymphoma

Therapeutic equivalent to prednisolone for

Malignant neoplasms of prostate

Therapeutic equivalent to prednisolone for

Hodgkin lymphoma

Therapeutic equivalent to prednisolone for

Anaplastic large cell lymphoma, ALK-negative

Therapeutic equivalent to prednisolone for

Anaplastic large cell lymphoma, ALK-positive

Therapeutic equivalent to prednisolone for

Langerhans cell histiocytosis

Therapeutic equivalent to prednisolone for

Lymphoid leukaemia, not elsewhere classified

Therapeutic equivalent to prednisolone for

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Therapeutic equivalent to prednisolone for

Diffuse large B-cell lymphoma, not otherwise specified

Antiallergics and medicines used in anaphylaxis

Therapeutic equivalent to prednisolone for

Allergic or hypersensitivity conditions of unspecified type

Adrenal hormones and synthetic substitutes

Oral > Solid > tablet: 1 mg

Therapeutic equivalent to prednisolone for

Adrenocortical insufficiency

Pretomanid

Section

Antituberculosis medicines

Oral > Solid > tablet: 200 mg

Indications

Multi-drug resistant Mycobacterium tuberculosis

Primaquine

Section

Antimalarial medicines > Medicines for curative treatment

Oral > Solid > tablet: 7.5 mg (as phosphate); 15 mg (as phosphate)

Indications

Malaria due to *Plasmodium ovale*

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Probenecid

Section

Medicines used to treat gout

Oral > Solid: 500 mg

Indications

Gout

Procainamide

Section

Antiarrhythmic medicines

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule (hydrochloride)

Oral > Solid: 500 mg (hydrochloride); 250 mg (hydrochloride)

Indications

Cardiac arrhythmia

Procaine benzylpenicillin

Section

Access group antibiotics

Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection

Indications

First choice

Congenital syphilis [children]

Second choice

Syphilis

Procarbazine

Section

Cytotoxic medicines

Oral > Solid: 50 mg (as hydrochloride)

Oral > Solid > capsule: 50 mg (as hydrochloride)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Hodgkin lymphoma

Progesterone vaginal ring

Section

Intravaginal contraceptives

Local > Vaginal > vaginal ring: 2.074 g micronized progesterone

Indications

Contact with health services for contraceptive management

Proguanil

Section

Antimalarial medicines > Medicines for chemoprevention

Oral > Solid: 100 mg tablet (hydrochloride)

Indications

Malaria due to *Plasmodium falciparum*

Promethazine

Section

Antiemetic medicines

Oral > Liquid: 5 mg per 5 mL (hydrochloride)

Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)

Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule

Indications

Nausea or vomiting

Propanol

Section

Antiseptics

Indications

Therapeutic equivalent to [ethanol](#) for

Denatured alcohol

Propofol

Section

General anaesthetics and oxygen > Injectable medicines

Parenteral > General injections > IV: 10 mg per mL; 20 mg per mL

Indications

Anaesthetics and therapeutic gases

Propranolol

Section

Antihypertensive medicines

Oral > Solid: 80 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)

Antianginal medicines

Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)

Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)

Antiarrhythmic medicines

Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)

Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)

Medicines for migraine prophylaxis

Oral > Solid > tablet: 40 mg (hydrochloride); 10 mg (hydrochloride)

Indications

Essential hypertension

Angina pectoris

Cardiac arrhythmia

Migraine

Propylthiouracil

Section

Thyroid hormones and antithyroid medicines
Oral > Solid: 50 mg

Indications

Thyrotoxicosis

Protamine sulfate

Section

Medicines affecting coagulation
Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule or vial

Indications

Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors

Protonamide

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to ethionamide for

Multi-drug resistant *Mycobacterium tuberculosis*

Pyrantel

Section

Intestinal anthelmintics
Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)

Indications

Ascariasis

Trichuriasis

Enterobiasis

Hookworm diseases

Pyrazinamide

Section

Antituberculosis medicines
Oral > Solid > dispersible tablet: 150 mg
Oral > Solid > tablet: 400 mg; 500 mg

Indications

Tuberculosis

Pyridostigmine

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
Parenteral > General injections > IV: 5 mg per mL in ampoule or vial (pyridostigmine bromide)

Oral > Solid > tablet: 60 mg scored (pyridostigmine bromide)

Medicines for myasthenia gravis

Parenteral > General injections > IV: 5 mg per mL in ampoule or vial (pyridostigmine bromide)

Oral > Solid > tablet: 60 mg scored (pyridostigmine bromide)

Indications

Myasthenia gravis

Myasthenia gravis

Pyridoxine

Section

Vitamins and minerals

Oral > Solid > tablet: 25 mg (hydrochloride); 10 mg (hydrochloride)

Indications

Other specified polyneuropathy

Vitamin B6 deficiency

Sideroblastic anaemia

Pyrimethamine

Section

Antipneumocystosis and antitoxoplasmosis medicines

Oral > Solid: 25 mg

Indications

Toxoplasmosis

Quetiapine

Section

Medicines for psychotic disorders

Medicines for bipolar disorders

Oral > Solid > tablet: 25 mg (immediate-release); 100 mg (immediate-release); 150 mg (immediate-release); 200 mg (immediate-release); 300 mg (immediate-release); 50 mg (modified-release); 150 mg (modified-release); 200 mg (modified-release); 300 mg (modified-release); 400 mg (modified-release)

Indications

Therapeutic equivalent to [risperidone](#) for

Schizophrenia or other primary psychotic disorders

Bipolar or related disorders

Quinidine

Section

Antiarrhythmic medicines

Oral > Solid: 200 mg (sulfate)

Indications

Cardiac arrhythmia

Quinine

Section

Antimalarial medicines > Medicines for curative treatment

Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion; 60 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion

Indications

Malaria due to *Plasmodium falciparum*

Rabies vaccine

Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against rabies

Raltegravir

Section

Antiretrovirals > Integrase inhibitors

Oral > Liquid: 100 mg granules for oral suspension

Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Ranibizumab

Section

Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

.

Indications

Retinal venous occlusions

Diabetic macular oedema

Degenerative high myopia

Age related macular degeneration

Ranitidine

Section

Antiulcer medicines

Oral > Liquid: 75 mg per 5 mL (as hydrochloride)

Oral > Solid: 150 mg (as hydrochloride)

Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)

Indications

Gastro-oesophageal reflux disease

Peptic ulcer, site unspecified

Rasburicase

Section	Indications
Supportive medicines Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution; 7.5 mg in vial powder and 5 mL solvent for solution	Tumour lysis syndrome

Ravidasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 200 mg	Chronic hepatitis C

Ready to use therapeutic food

Section	Indications
Therapeutic foods Biscuit or paste of nutritional composition as determined by the UN joint statement on the community-based management of severe acute malnutrition and Codex alimentarius guidelines.	Acute malnutrition in infants, children or adolescents

Realgar-indigo naturalis formulation

Section	Indications
Cytotoxic medicines Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)	Acute myeloid leukaemia with recurrent genetic abnormalities

Red blood cells

Section	Indications
Blood and blood components Parenteral > General injections > IV:	Blood transfusion without reported diagnosis

Resin-based composite (high-viscosity)

Section	Indications
Dental medicines and preparations Local > Topical > Other: Single-use capsule or multi-use syringe	Dental caries

Resin-based composite (low-viscosity)

Section	Indications
Dental medicines and preparations Local > Topical > Other: Single-use applicator or multi-use bottle	Dental caries

Respiratory syncytial virus vaccine

Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Retinol

Section

Vitamins and minerals

Parenteral > General injections > IM: 50000 IU per mL in 2 mL ampoule or vial water-miscible (as palmitate)

Oral > Liquid: 100000 IU per mL (as palmitate or acetate)

Oral > Solid > capsule: 200000 IU (as palmitate or acetate) soft capsule; 50000 IU (as palmitate); 100000 IU (as palmitate or acetate) soft capsule

Indications

Vitamin A deficiency

Ribavirin

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution

Oral > Solid: 200 mg; 400 mg; 600 mg

Other antivirals

Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution

Oral > Solid: 200 mg; 400 mg; 600 mg

Indications

Chronic hepatitis C

Viral haemorrhagic fever, not elsewhere classified

Ribociclib

Section

Targeted therapies

Indications

Therapeutic equivalent to palbociclib for

Other specified malignant neoplasms of breast

Riboflavin

Section

Vitamins and minerals

Oral > Solid: 5 mg

Indications

Vitamin B2 deficiency

Rifabutin

Section

Antituberculosis medicines

Oral > Solid: 150 mg

Indications

Tuberculosis

Rifampicin

Section

Antituberculosis medicines

Oral > Liquid: 20 mg per mL

Oral > Solid: 150 mg; 300 mg

Parenteral > General injections > IV: 600 mg in vial powder for injection

Antileprosy medicines

Oral > Liquid: 20 mg per mL

Oral > Solid: 150 mg; 300 mg

Indications

Tuberculosis

Other specified tuberculosis

Leprosy

Rifapentine

Section

Antituberculosis medicines

Oral > Solid > tablet: 150 mg; 300 mg

Oral > Solid > dispersible tablet: 150 mg

Indications

Tuberculosis

Latent tuberculosis

Risdiplam

Section

Medicines for neurological disorders

Oral > Liquid: 0.75 mg per mL powder for oral liquid

Oral > Solid > dispersible tablet: 5 mg

Indications

Spinal muscular atrophy

Risperidone

Section

Medicines for psychotic disorders

Oral > Solid: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg; 6 mg

Parenteral > General injections > IM:

Indications

Schizophrenia or other primary psychotic disorders

Therapeutic equivalent to [paliperidone](#) for

Schizophrenia or other primary psychotic disorders

Ritonavir

Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Rituximab

Section

Targeted therapies

Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial

Medicines for multiple sclerosis

Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial

Indications

Follicular lymphoma

Burkitt lymphoma including Burkitt leukaemia

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Diffuse large B-cell lymphoma, not otherwise specified

Multiple sclerosis

Rivaroxaban

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to dabigatran for

Venous thromboembolism

Therapeutic equivalent to dabigatran for

Other specified atrial fibrillation

Ropinirole

Section

Antiseizure medicines

Oral > Solid: 0.25 mg immediate-release; 0.5 mg immediate-release; 1 mg immediate-release; 2 mg immediate-release; 3 mg immediate-release; 4 mg immediate-release; 5 mg immediate-release; 2 mg extended-release; 4 mg extended-release; 6 mg extended-release; 8 mg extended-release; 12 mg extended-release

Indications

Parkinson disease

Rotavirus vaccine

Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Rubella vaccine

Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against rubella alone

Salbutamol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Parenteral > General injections > IV: 500 µg per mL in 1 mL ampoule (as sulfate); 500 µg per mL in 5 mL ampoule (as sulfate)

Respiratory > Inhalation > solution: 100 µg per actuation in pressurized metered dose inhaler (as sulfate); 2.5 mg per 2.5 mL in 2.5 mL ampoule (as sulfate) for use in nebulizers; 5 mg per 2.5 mL in 2.5 mL ampoule (as sulfate) for use in nebulizers; 5 mg per mL in multi-dose bottle (as sulfate) for use in nebulizers

Indications

Chronic obstructive pulmonary disease

Asthma

Salicylic acid

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Local > Topical > Solution: 5%

Indications

Seborrhoeic dermatitis

Psoriasis of unspecified type

Ichthyoses

Saquinavir

Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 200 mg; 500 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Selenium sulfide

Section

Dermatological medicines > Antifungal medicines

Local > Topical > Suspension: 2% detergent-based

Indications

Seborrhoeic dermatitis

Pityriasis versicolor

Semaglutide

Section

Hypoglycaemic agents

Parenteral > General injections > SC: 0.25 mg in pre-filled pen injection solution; 0.5 mg in pre-filled pen injection solution; 1 mg in pre-filled pen injection solution; 2 mg in pre-filled pen injection solution; 4 mg in pre-filled pen injection solution

Oral > Solid > tablet: 3 mg

Parenteral > General injections > SC: 0.68 mg per mL; 1.34 mg per mL; 2.68 mg per mL

Indications

Obesity

Type 2 diabetes mellitus

Senna

Section

Medicines for other common symptoms in palliative care

Oral > Liquid: 7.5 mg per 5 mL oral liquid

Laxatives

Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms)

Indications

Palliative care

Constipation

Sevoflurane

Section

General anaesthetics and oxygen > Inhalational medicines

Respiratory > Inhalation > liquid:

Indications

Anaesthetics and therapeutic gases

Silver diamine fluoride

Section

Dental medicines and preparations

Local > Dental > Solution: 38% w/v

Indications

Dental caries

Silver nitrate

Section

Ophthalmological preparations > Anti-infective agents

Local > Ophthalmological > Solution (eye drops): 1%

Indications

Neonatal conjunctivitis or dacryocystitis

Silver sulfadiazine

Section

Dermatological medicines > Anti-infective medicines

Local > Topical > Cream: 1%

Indications

Burns

Simeprevir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
Oral > Solid: 150 mg

Indications

Chronic hepatitis C

Simvastatin

Section

Lipid-lowering agents
Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg

Medicines for endocrine disorders
Oral > Solid: 20 mg

Indications

Mixed hyperlipidaemia

Coronary atherosclerosis

Polycystic ovary syndrome

Smallpox vaccine

Section

Immunologicals > Vaccines
All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Snake antivenom

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies
.

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Sodium calcium edetate

Section

Antidotes and other substances used in poisonings > Specific
Parenteral > General injections > IV: 200 mg per mL in 5 mL ampoule

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Sodium chloride

Section

Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na⁺ 154 mmol/L and Cl⁻ 154 mmol/L)

Indications

Other specified disorders of fluid, electrolyte or acid-base balance

Sodium hyaluronate

Section

Ophthalmological preparations

Indications

Therapeutic equivalent to [hypromellose](#) for

Keratoconjunctivitis sicca

Sodium hydrogen carbonate

Section

Solutions correcting water, electrolyte and acid-base disturbances >
Parenteral

Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na⁺ 167 mmol/L and HCO₃⁻ 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na⁺ 1000 mmol/L and HCO₃⁻ 1000 mmol/L)

Indications

Acidosis

Sodium nitrite

Section

Antidotes and other substances used in poisonings > Specific
Parenteral > General injections > IV: 30 mg per mL in 10 mL ampoule

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Sodium nitroprusside

Section

Antihypertensive medicines
Parenteral > General injections > IV: 50 mg in ampoule powder for infusion

Indications

Hypertensive crisis

Sodium stibogluconate

Section

Antileishmaniasis medicines
Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial

Indications

Visceral leishmaniasis

Mucocutaneous leishmaniasis

Cutaneous leishmaniasis

Sodium thiosulfate

Section	Indications
Dermatological medicines > Antifungal medicines Local > Topical > Solution: 15%	Pityriasis versicolor
Antidotes and other substances used in poisonings > Specific Parenteral > General injections > IV: 250 mg per mL in 50 mL ampoule	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Sofosbuvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 200 mg; 400 mg Oral > Solid > granules: 200 mg in sachet	Chronic hepatitis C

Sofosbuvir + velpatasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg Oral > Solid > granules: 150 mg + 37.5 mg in sachet; 200 mg + 50 mg in sachet	Chronic hepatitis C

Somatropin

Section	Indications
Medicines for endocrine disorders Parenteral > General injections > SC: 5 mg in cartridge powder for injection; 5 mg per mL in 2 mL cartridge	Hypoglycaemia without associated diabetes

Spectinomycin

Section	Indications
Access group antibiotics Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection	Second choice Gonococcal infection
	Other indications Bacterial infection of unspecified site

Spironolactone

Section	Indications
Medicines used in heart failure Oral > Solid > tablet: 25 mg	Heart failure
Diuretics Oral > Liquid: 25 mg per 5 mL Oral > Solid > tablet: 25 mg; 12.5 mg	Oedema Ascites

Stavudine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Liquid: 5 mg per 5 mL powder for oral solution Oral > Solid: 15 mg; 20 mg; 30 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Streptokinase

Section	Indications
Thrombolytic medicines Parenteral > General injections > IV: 1.5 million IU in vial powder for injection	Acute myocardial infarction

Streptomycin (injection)

Section	Indications
Antituberculosis medicines Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial	Multi-drug resistant Mycobacterium tuberculosis

Succimer

Section	Indications
Antidotes and other substances used in poisonings > Specific Oral > Solid: 100 mg	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Sulfacetamide

Section	Indications
Ophthalmological preparations > Anti-infective agents Local > Ophthalmological > Ointment: 10% (sodium salt)	Other specified conjunctivitis

Sulfadiazine

Section

Antipneumocystosis and antitoxoplasmosis medicines

Oral > Solid: 500 mg

Anti-infective medicines

Oral > Solid: 500 mg

Parenteral > General injections > unspecified: 250 mg in 4 mL ampoule (sodium salt)

Indications

Toxoplasmosis

Bacterial infection of unspecified site

Sulfadimidine

Section

Anti-infective medicines

Oral > Liquid: 500 mg per 5 mL

Oral > Solid: 500 mg

Parenteral > General injections > unspecified: 1 g in 3 mL ampoule (sodium salt)

Indications

Bacterial infection of unspecified site

Sulfadoxine + pyrimethamine

Section

Antimalarial medicines > For chemoprevention

Oral > Solid: 500 mg + 25 mg tablet

Antimalarial medicines > Medicines for curative treatment

Oral > Solid: 500 mg + 25 mg tablet

Antimalarial medicines > Medicines for chemoprevention

Oral > Solid > dispersible tablet: 250 mg + 12.5 mg tablet

Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Malaria

Sulfamethoxazole + trimethoprim

Section	Indications
Access group antibiotics Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet Oral > Solid > dispersible tablet: 100 mg + 20 mg	First choice Infectious cystitis Second choice Infectious gastroenteritis or colitis without specification of infectious agent Other indications Bacterial infection of unspecified site Pneumocystosis
Antipneumocystosis and antitoxoplasmosis medicines Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet Oral > Solid > dispersible tablet: 100 mg + 20 mg	

Sulfasalazine

Section	Indications
Disease-modifying anti-rheumatic drugs (DMARDs) Oral > Solid: 500 mg	Rheumatoid arthritis, serology unspecified
Anti-inflammatory medicines Oral > Solid: 500 mg Local > Rectal > Suppository: 500 mg Local > Rectal > Retention enema: 3 g per 100 mL	Crohn disease site Ulcerative colitis

Sumatriptan

Section	Indications
Medicines for acute migraine attacks Oral > Solid > tablet: 50 mg	Migraine
Medicines for cluster headache Parenteral > General injections > SC: 6 mg per 0.5 mL in pre-filled pen; 6 mg per 0.5 mL in pre-filled syringe	Trigeminal autonomic cephalalgias

Sunscreen, broad-spectrum

Section

Dermatological medicines

Topical cream, lotion, gel, ointment, spray with sun protection factor $\geq$ 50.

Dermatological medicines > Sunscreens

Topical:

Therapeutic broad-spectrum sunscreens should contain proven active ingredients in appropriate amounts to absorb or filter UVA and UVB radiation, and have a high sun protection factor (SPF).

Indications

Xeroderma pigmentosum

Albinism or other specified genetically-determined hypomelanotic disorders

Suramin sodium

Section

Antifilarials

Parenteral > General injections > IV: 1 g in vial

Medicines for the treatment of 1st stage African trypanosomiasis

Parenteral > General injections > IV: 1 g in vial

Indications

Filariasis

Rhodesiense trypanosomiasis

Suxamethonium

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

Parenteral > General injections > IV: 50 mg per mL in 2 mL ampoule (chloride)

Indications

Muscle relaxants

Tacalcitol

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to [calcipotriol](#) for

Psoriasis of unspecified type

Tacrolimus

Section

Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 5 mg per mL in 1 mL vial

Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension

Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)

Indications

Failure or rejection of transplanted organs or tissues

Tamoxifen

Section

Hormones and antihormones

Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)

Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

Tedizolid

Section

Reserve group antibiotics

Indications

Therapeutic equivalent to *linezolid* for

Methicillin resistant *Staphylococcus aureus*

Therapeutic equivalent to *linezolid* for

Vancomycin resistant *Staphylococcus aureus*

Therapeutic equivalent to *linezolid* for

Vancomycin resistant *Enterococcus*

Telmisartan + amlodipine

Section

Antihypertensive medicines

Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg

Indications

Essential hypertension

Telmisartan + hydrochlorothiazide

Section

Antihypertensive medicines

Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg

Indications

Essential hypertension

Temozolomide

Section

Cytotoxic medicines

Parenteral > General injections > IV: 100 mg in vial powder for injection

Oral > Solid > capsule: 5 mg; 20 mg; 100 mg; 140 mg; 180 mg; 250 mg

Indications

Ewing sarcoma of bone and articular cartilage of unspecified sites

Other specified gliomas of brain

Unspecified malignant neoplasms of ill-defined or unspecified sites

Neuroblastoma, NOS

Tenofovir alafenamide

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Solid: 25 mg

Indications

Chronic hepatitis B

Tenofovir disoproxil fumarate

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Contact with or exposure to human immunodeficiency virus

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Chronic hepatitis B

Terbinafine

Section

Dermatological medicines > Antifungal medicines
Local > Topical > Cream: 1% terbinafine hydrochloride
Local > Topical > Ointment: 1% terbinafine hydrochloride

Indications

Fungal infection of the skin

Terbutaline

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to salbutamol for

Chronic obstructive pulmonary disease

Therapeutic equivalent to salbutamol for

Asthma

Terizidone

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to cycloserine for

Multi-drug resistant Mycobacterium tuberculosis

Testosterone

Section	Indications
Androgens Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)	Testicular dysfunction or testosterone-related disorders

Tetanus antitoxin

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies Parenteral > General injections > IM: 50000 IU in vial	Tetanus

Tetanus vaccine

Section	Indications
Immunologicals > Vaccines All vaccines should comply with the WHO requirements for biological substances.	Need for immunization against tetanus alone

Tetracaine

Section	Indications
Ophthalmological preparations > Local anaesthetics Local > Ophthalmological > Solution (eye drops): 0.5% (hydrochloride)	Local anaesthetics

Tetracycline

Section	Indications
Access group antibiotics Oral > Solid: 250 mg (hydrochloride)	Bacterial infection of unspecified site
Ophthalmological preparations > Anti-infective agents Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)	Neonatal conjunctivitis or dacryocystitis
	Other specified conjunctivitis
	Infectious keratitis
	Infectious blepharitis
	Trachoma

Thalidomide

Section	Indications
Immunomodulators Oral > Solid: 50 mg	Plasma cell myeloma

Thiamine

Section

Vitamins and minerals

Parenteral > General injections > IV: 50 mg per mL in ampoule or vial (hydrochloride)

Oral > Solid > tablet: 50 mg (hydrochloride)

Indications

Vitamin B1 deficiency

Thiopental

Section

General anaesthetics and oxygen > Injectable medicines

Indications

Therapeutic equivalent to propofol for

Anaesthetics and therapeutic gases

Ticagrelor

Section

Anti-platelet medicines

Oral > Solid > tablet: 60 mg; 90 mg

Indications

Acute ischaemic heart disease

Presence of coronary angioplasty implant or graft

Tick-borne encephalitis vaccine

Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against arthropod-borne viral encephalitis

Tigecycline

Section

Reserve group antibiotics

Parenteral > General injections > IV: 50 mg in vial powder for injection

Indications

Other specified bacterial diseases

Timolol

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)

Indications

Primary open-angle glaucoma

Ocular hypertension

Tinidazole

Section

Antiamoebic and anti giardiasis medicines

Indications

Therapeutic equivalent to [metronidazole](#) for

Amoebiasis

Tioguanine

Section

Cytotoxic medicines

Oral > Solid: 40 mg

Indications

Lymphoid leukaemia, not elsewhere classified

Tiotropium bromide

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Respiratory > Inhalation > powder: 18 µg in capsule

Respiratory > Inhalation > solution: 1.25 µg per actuation in soft mist inhaler; 2.5 µg per actuation in soft mist inhaler

Indications

Chronic obstructive pulmonary disease

Tirzepatide

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for

Obesity

Therapeutic equivalent to [semaglutide](#) for

Type 2 diabetes mellitus

Tisagenlecleucel

Section

Antineoplastics and supportive medicines

Indications

Therapeutic equivalent to [axicabtagene ciloleucel](#) for

Diffuse large B-cell lymphomas

Tislelizumab

Section	Indications
Immunomodulators	Malignant neoplasms of urinary tract
Parenteral > General injections > IV: 100 mg per 10 mL	Hodgkin lymphoma
Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion	Other specified malignant neoplasms of bronchus or lung
Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion	Squamous cell carcinoma of oesophagus

Tobramycin

Section	Indications
Ophthalmological preparations > Anti-infective agents	Therapeutic equivalent to gentamicin for
	Other specified conjunctivitis
	Therapeutic equivalent to gentamicin for
	Infectious blepharitis

Tocilizumab

Section	Indications
Medicines for juvenile joint diseases	Juvenile systemic arthritis
Parenteral > General injections > IV: 80 mg per 4 mL in vial; 200 mg per 10 mL in vial; 400 mg per 20 mL in vial	
Parenteral > General injections > SC: 162 mg per 0.9 mL in pre-filled syringe	

Tolbutamide

Section	Indications
Oral hypoglycaemic agents	Type 2 diabetes mellitus
Oral > Solid: 500 mg	

Torase mide

Section

Medicines used in heart failure

Diuretics

Indications

Therapeutic equivalent to furosemide for

Heart failure

Therapeutic equivalent to furosemide for

Anuria or oliguria

Therapeutic equivalent to furosemide for

Oedema

Toripalimab

Section

Immunomodulators

Parenteral > General injections > IV: 240 mg per 6 mL in vial

Indications

Malignant neoplasms of nasopharynx

Squamous cell carcinoma of oesophagus

Tramad ol

Section

Opioid analgesics

Oral > Liquid: 100 mg per mL (hydrochloride)

Oral > Solid: 50 mg (hydrochloride) immediate release; 50 mg (hydrochloride) controlled release; 100 mg (hydrochloride) controlled release; 150 mg (hydrochloride) controlled release; 200 mg (hydrochloride) controlled release; 300 mg (hydrochloride) controlled release; 400 mg (hydrochloride) controlled release

Parenteral > General injections > unspecified: 50 mg per mL in 2 mL ampoule (hydrochloride)

Indications

Chronic cancer pain

Trametinib

Section

Targeted therapies

Oral > Solid: 0.5 mg; 2 mg

Indications

Other specified melanoma of skin

Tranexamic acid

Section	Indications
Medicines affecting coagulation Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule	Haemorrhage, not elsewhere classified
Other medicines administered to the mother Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule	Postpartum haemorrhage

Trastuzumab

Section	Indications
Targeted therapies Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection	Carcinoma of breast, specialised type

Trastuzumab emtansine

Section	Indications
Targeted therapies Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection	Carcinoma of breast, specialised type

Tremelimumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion	Hepatocellular carcinoma of liver Other specified malignant neoplasms of bronchus or lung

Triamcinolone hexacetonide

Section	Indications
Medicines for juvenile joint diseases Parenteral > Locoregional injections > Intra-articular: 20 mg per mL in vial	Juvenile idiopathic arthritis

Triclabendazole

Section	Indications
Antischistosomes and other antitremitode medicines Oral > Solid > tablet: 250 mg (scored)	Paragonimiasis Fascioliasis

Trihexyphenidyl

Section

Antiseizure medicines

Oral > Solid: 2 mg (hydrochloride); 5 mg (hydrochloride)

Medicines for parkinsonism

Indications

Parkinson disease

Therapeutic equivalent to [biperiden](#) for

Parkinson disease

Trimethoprim

Section

Access group antibiotics

Oral > Liquid: 50 mg per mL

Oral > Solid: 100 mg; 200 mg

Indications

First choice

Infectious cystitis

Triptorelin

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [leuporelin](#) for

Malignant neoplasms of breast

Therapeutic equivalent to [leuporelin](#) for

Malignant neoplasms of prostate

Tropicamide

Section

Diagnostic agents > Ophthalmic medicines

Local > Ophthalmological > Solution (eye drops): 0.5%

Indications

Cycloplegic drug

Tropisetron

Section

Medicines for other common symptoms in palliative care

Indications

Therapeutic equivalent to [ondansetron](#) for

Palliative care

Antiemetic medicines

Therapeutic equivalent to [ondansetron](#) for

Nausea or vomiting

Tuberculin, purified protein derivative

Section

Immunologicals > Diagnostic agents

Parenteral > Locoregional injections > Intradermal:

Indications

Mycobacterial diseases

Tubocurarine

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

Parenteral > General injections > IV: 10 mg per mL in 1.5 mL ampoule (tubocurarine chloride)

Indications

Muscle relaxants

Typhoid vaccine

Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against typhoid-paratyphoid alone

Ulipristal

Section

Oral hormonal contraceptives

Oral > Solid: 30 mg tablet (ulipristal acetate)

Indications

Contact with health services for postcoital contraception

Umeclidinium

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to tiotropium bromide for

Chronic obstructive pulmonary disease

Urea

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Local > Topical > Cream: 10%; 5%

Local > Topical > Ointment: 10%; 5%

Dermatological medicines > Moisturizers

Local > Topical > Cream: 5 per %

Indications

Xerosis cutis or asteatosis

Atopic eczema

Ustekinumab

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Parenteral > General injections > SC: 45 mg per 0.5 mL in vial; 45 mg per 0.5 mL in pre-filled syringe; 45 mg per 0.5 mL in pre-filled pen; 90 mg per mL in pre-filled syringe; 90 mg per mL in pre-filled pen

Indications

Psoriasis of unspecified type

Valaciclovir

Section

Antiherpes medicines

Medicines for viral central nervous system infections

Indications

Therapeutic equivalent to [aciclovir](#) for

Zoster

Therapeutic equivalent to [aciclovir](#) for

Varicella

Therapeutic equivalent to [aciclovir](#) for

Herpes simplex infections

Therapeutic equivalent to [aciclovir](#) for

Herpes simplex infections

Therapeutic equivalent to [aciclovir](#) for

Zoster

Therapeutic equivalent to [aciclovir](#) for

Varicella

Valganciclovir

Section

Other antivirals

Oral > Liquid: 50 mg per mL (as hydrochloride) powder for oral solution

Oral > Solid > tablet: 450 mg (as hydrochloride)

Indications

Cytomegaloviral retinitis

Valproic acid (sodium valproate)

Section	Indications
Medicines for bipolar disorders Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)	Bipolar or related disorders
Antiseizure medicines Oral > Liquid: 200 mg per 5 mL Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable) Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 3 mL ampoule	Epilepsy or seizures Status epilepticus

Valsartan + amlodipine + hydrochlorothiazide

Section	Indications
Antihypertensive medicines Oral > Solid > dosage form: 160 mg + 5 mg + 12.5 mg; 160 mg + 5 mg + 25 mg; 160 mg + 10 mg + 12.5 mg; 160 mg + 10 mg + 25 mg; 320 mg + 10 mg + 25 mg	Essential hypertension

Vancomycin

Section	Indications
Watch group antibiotics Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride) Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection	First choice Necrotising fasciitis co-prescribed with ceftazidime Endophthalmitis co-prescribed with ceftriaxone Endophthalmitis Second choice Neutropenia (high-risk) Intestinal infections due to Clostridioides difficile
	Other indications Methicillin resistant Staphylococcus aureus

Varenicline

Section	Indications
Medicines for nicotine use disorders Oral > Solid: 0.5 mg; 1 mg	Nicotine dependence

Varicella vaccine

Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Vecuronium

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

Parenteral > General injections > IV: 10 mg in vial powder for injection (vecuronium bromide)

Indications

Muscle relaxants

Vemurafenib

Section

Targeted therapies

Indications

Therapeutic equivalent to dabrafenib for

Other specified melanoma of skin

Verapamil

Section

Antiarrhythmic medicines

Parenteral > General injections > IV: 2.5 mg per mL in 2 mL ampoule (hydrochloride)

Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)

Antianginal medicines

Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)

Medicines for cluster headache

Oral > Solid > tablet: 120 mg (hydrochloride) (immediate-release); 40 mg (hydrochloride) (immediate-release); 80 mg (hydrochloride) (immediate-release); 120 mg (hydrochloride) (extended-release); 180 mg (hydrochloride) (extended-release); 240 mg (hydrochloride) (extended-release)

Indications

Supraventricular tachyarrhythmia

Angina pectoris

Trigeminal autonomic cephalalgias

Vinblastine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate) Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)	Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Kaposi sarcoma of unspecified primary site Hodgkin lymphoma Other specified malignant neoplasms of the ovary Germ cell tumour of testis Anaplastic large cell lymphoma, ALK-positive Anaplastic large cell lymphoma, ALK-negative Langerhans cell histiocytosis

Vincristine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate) Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)	Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Malignant trophoblastic neoplasms of placenta Follicular lymphoma Kaposi sarcoma of unspecified primary site Rhabdomyosarcoma primary site Hodgkin lymphoma Retinoblastoma Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Langerhans cell histiocytosis Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Diffuse large B-cell lymphoma, not otherwise specified

Vinorelbine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial Oral > Solid > capsule: 20 mg; 30 mg; 80 mg	Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of breast Rhabdomyosarcoma primary site

Voriconazole

Section	Indications
Antifungal medicines Parenteral > General injections > IV: 200 mg in vial powder for injection Oral > Liquid: 40 mg per mL powder for oral liquid Oral > Solid: 50 mg tablet; 200 mg tablet	Chronic pulmonary aspergillosis Invasive aspergillosis

Warfarin

Section	Indications
Medicines affecting coagulation Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium) Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium)	Other specified diseases of arteries or arterioles Venous thromboembolism Cerebral ischaemic stroke due to embolic occlusion Atrial fibrillation

Water for injection

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Miscellaneous Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule	Unspecified appropriateness of dosing or administration without injury or harm

Whole blood

Section	Indications
Blood and blood components Parenteral > General injections > IV:	Blood transfusion without reported diagnosis

Xylometazoline

Section

Ear, nose and throat medicines [c]

Local > Nasal > Spray: 0.05% equivalent to 0.5 mg per mL

Local > Nasal > Drops: 0.05% equivalent to 0.5 mg per mL

Indications

Nasal congestion

Yellow fever vaccine

Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Zanubrutinib

Section

Targeted therapies

Oral > Solid: 80 mg

Oral > Solid > capsule: 80 mg

Indications

Mantle cell lymphoma

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Therapeutic equivalent to ibrutinib for

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Zidovudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion

Oral > Liquid: 50 mg per 5 mL

Oral > Solid > tablet: 300 mg

Oral > Solid > capsule: 250 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Zinc sulfate

Section

Medicines for diarrhoea

Oral > Solid > dispersible tablet: 20 mg (scored)

Indications

Diarrhoea

Zoledronic acid

Section

Supportive medicines

Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

Medicines for endocrine disorders

Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

Indications

Malignant neoplasm metastasis in bone or bone marrow

Osteogenesis imperfecta

Zuclopenthixol decanoate

Section

Medicines for psychotic disorders

Indications

Therapeutic equivalent to fluphenazine for

Schizophrenia or other primary psychotic disorders